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ABSTRACT 
 
The focus of this research was to apply mathematical and computational methods for 
modelling and prediction of tumour volume during the course of radiotherapy. The developed 
tools could provide valuable information for the optimisation of radiotherapy in the future. 
Firstly, the feasibility of modelling tumour volume dynamics of individual patients, as 
measured by computed tomography (CT) imaging, was explored. The main objective was to 
develop a model that is adequate to describe tumour volume dynamics, and at the same time is 
not excessively complex as lacking support from clinical data. To this end, various modelling 
options were explored, and rigorous statistical methods, the Akaike information criterion (AIC) 
and the corrected Akaike information criterion (AICc), were used for model selection. The 
models were calibrated to data from two cohorts of non-small cell lung cancer patients, one 
treated by stereotactic ablative radiotherapy and the other by conventionally fractionated 
radiotherapy. The results showed that a two-population model with exponential tumour growth 
is the most appropriate for the data studied as judged by AIC and AICc. Secondly, this model 
was further equipped with a Bayesian adaption approach in order to predict individual patients‘ 
response to radiotherapy in terms of tumour volume change during the treatment. The main 
idea was to start from a population-average model, which is subsequently updated, using 
Bayesian parameter estimation, from an individual‘s tumour volume measurement. Therefore 
the model becomes more and more personalised and so is the prediction. The usefulness of the 
developed method was demonstrated on clinical data. Finally, attempt was made to link the 
predicted tumour volume (an important but often secondary treatment outcome indicator) to 
tumour control probability (one of the primary indicators of treatment outcome), and this 
model was demonstrated through a simulation study. Overall this research has contributed new 
methods and results of mathematical modelling for quantitatively analysis and prediction of 
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individual patients‘ response to radiotherapy; it represents a significant development that could 
be used for improved and personalised planning and scheduling of radiotherapy in the future. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
Cancer is the name given to a class of diseases characterised by an imbalance in cell 
proliferation and apoptosis (Harrold & Parker, 2009). It is one of the main reasons of 
morbidity and mortality and causes millions of deaths every year around the world. 
According to the World Health Organization (www.who.int), 7.9 million people (13% of total 
deaths) died of cancer in 2007 and it was projected that it may increase 52% by 2030. Now in 
2015, 2.5 million people in UK were diagnosed with cancer (www.macmillan.org.uk). The 
reasons for such alarming trends include the lack of definite therapy for all types of cancer 
(Jemal et al., 2010; www.ons.gov.uk).  
Among available treatment methods, radiotherapy is the second only to surgery in the 
care and cure of cancer (Joiner & Kogel, 2009). Radiotherapy aims to use radiation to kill 
tumour cells, while limiting damage to the surrounding normal tissues. Therefore, a 
fundamental task of radiotherapy is to understand and predict the response of tumour and 
normal tissues to treatment.  This research is focused on the tumour response; in particular, 
the modelling and prediction of tumour volume change during the course of radiotherapy and 
subsequent treatment outcome, which could provide useful information about treatment 
efficacy. 
In this research, tumour response is characterised by volume change, since tumour 
volume is a well-known and important predictor of treatment outcome (Bral et al., 2009; 
Bentzen & Thames, 1996; Dubben et al., 1998; Mozley et al., 2012; Willner et al., 2002). 
However, in the past, tumour volume was typically measured from computed tomography 
(CT), and for certain sites magnetic resonance imaging (MRI), scans only before and after 
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treatment. For fractionated radiotherapy, the entire treatment (with a total dose of e.g. 64 Gy) 
can last from several days to several weeks with one fraction of radiation (e.g. 2 Gy) 
delivered per day. If the tumour volume can be assessed at multiple time instances during 
treatment, it could provide more timely indication of tumour response. Arguably, the original 
intention of daily imaging and tumour volume/shape assessment is to adapt the three-
dimensional dose distribution, so as to minimise radiation to normal tissue.  A recent critical 
review of evidence on the change in lung tumour volume as a biomarker of treatment 
response has indicated that there are circumstances where volumetric image analysis adds 
value in term of patient treatment (Mozley et al., 2012). However, PET (Positron emission 
tomography) based tumour delineation methods have been used to provide tumour size in 
agreement with pathology (Cheebsumon et al., 2012). A number of studies have indicated the 
value of PET/CT in lung tumour volume delineation (e.g. Greco et al., 2007), PET/CT does 
not provide an easily implemented solution to monitoring tumour volume dynamics during 
treatment, which could be used as early indication of outcome. Recently, this detection of 
tumour volume dynamics has been made possibly by wide adoption of image-guided 
radiotherapy (IGRT), e.g. megavoltage CT enabled Tomotherapy and cone-beam CT based 
systems (Burnet et al., 2010; Loo et al., 2011; Xing et al., 2006).  
By definition, IGRT relies on imaging to improve patient set up accuracy and radiation 
dose conformity between fractions. As a ―by-product‖, the tumour volume can be measured 
at multiple time points, including before the delivery of each fraction, generating a large 
amount of data. As a result, there has been substantial interest in assessing the dynamics of 
tumour volume during radiotherapy (Barker et al., 2004; Loo et al., 2011; Woodford et al., 
2007). It should be noted that although CT images can provide more detailed information, 
such as the change of radio-density in the Hounsfield scale or tumour heterogeneity reflected 
by image textures (Ganeshan et al., 2012), gross tumour volume (GTV) is still the most 
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widely used metric to assess response to therapy (Huang et al., 2010) . The availability of 
such generated data has significant research interest. For example, the potential of using the 
time-profile of GTV for prognosis and predictive purposes has been reported; it seems 
possible that an individual patient‘s response can be reflected by the way GTV changes (Bral 
et al., 2009; Woodford et al., 2007). To this end, the use of mathematical models has started 
to emerge (detailed review in Chapter 2).  
Within this line of research, various models have been developed in an attempt to 
describe and predict how tumour volume changes over time. Nevertheless, significant gaps 
still exist. First, the models developed so far have not been fully interrogated in terms of the 
balance between the accuracy of fitting the data and model complexity. It is well known, 
from systems engineering perspective, that more complex models usually give better fitting 
to the data but become less useful when used for prediction purposes. Second, how the 
models can be used to predict the response of individual patients during the treatment has not 
been demonstrated. Third, previous research has not explored the methods to linking the 
tumour volume dynamics model to measures of treatment outcome, such as tumour control 
probability (TCP). It should be noted that volume is a useful but only secondary end-point; 
treatment outcome is of primary interest. The potential use of appropriate model is the 
personalised prediction of GTV and TCP, thus the model could support personalised 
optimisation of radiotherapy. These gaps motivated the present research.   
 
1.2 Objectives and contributions 
The overall aim of this research is to develop mathematical modelling methods for the 
analysis and prediction of tumour volume dynamics and treatment outcome under 
radiotherapy; these methods could be used in the future for the optimisation of radiotherapy 
of individual patients. The specific objectives are: 
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1) To develop a model, with the application of system engineering model selection 
approach, so that it is adequate to describe tumour volume change measured during 
radiotherapy by exploration of different mathematical models, and to validate the 
models using clinical data from radiotherapy of non-small cell lung cancer (NSCLC). 
2) To develop a Bayesian adaptation approach so that the model can be rapidly updated 
to individual patients and thus to provide more accurate and timely prediction. 
3) To develop a method that links tumour volume with tumour control probability so that 
the clinical outcome can be predicted for individual patient.  
Two sets of clinical data are available to support the model development.  One data set 
contained 11 patients of early stage NSCLC under stereotactic ablative radiotherapy (SABR) 
and the other having 25 patients of late stage NSCLC under tomotherapy. Both SABR and 
tomotherapy are the forms of radiotherapy . Both sets of clinical data are presented in Chapter 
3.  
Through achieving the objectives, this research has made the following contributions to 
the multi-disciplinary field of cancer modelling: 
 The first application of a systems approach for the assessment of the suitability of 
various tumour dynamic models in terms of the balance between modelling accuracy 
and complexity. It was observed that a relatively simple model, including two 
populations of cancer cells (living and dead) with exponential growth kinetics, is the 
most appropriate for describing the tumour volume data. Although this model has 
been reported in the literature, a rigorous model selection study has not been 
attempted until this research. In addition, modelling the tumour dynamics specifically 
of SABR was first reported from this research. 
 The application of Bayesian adaptation method for predicting the progression of 
tumour volume during the course of radiotherapy. The concept and method of 
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adaptive prediction are in contrast to existing modelling studies whose focus was on 
fitting to clinical data. The adaptive approach is attractive because it utilises all 
information of an individual patient available so far to predict what could happen 
towards the end of the treatment; this prediction could be useful for timely 
adjustment of the treatment schedule in light of an individual‘s response to 
radiotherapy (and the large inter-patient variability in response to radiotherapy is well 
known). 
 The development of a method that links adaptive prediction of tumour volume to 
adaptive prediction of tumour control probability (TCP), a clinically important end-
point of radiotherapy. Although due to the lack of clinical data, this method was only 
demonstrated through simulation studies, it laid a foundation for future exploration of 
this line of research. 
 
1.3 Overview of the remaining chapters  
The remaining chapters are organised as follows. Chapter 2 provides a detailed review of 
literature that is relevant to the thesis, including the biological aspects of cancer and 
radiotherapy physics, tumour modelling and parameter estimation. Chapter 3 introduces the 
two data sets of NSCLC patients, one cohort treated by SABR and the other by 
conventionally fractionated radiotherapy (specifically tomotherapy). Chapter 4 presents the 
study of modelling and model selection with respect to tumour volume dynamics; it results in 
a specific model (two-population model with exponential tumour growth) that will be brought 
forward for the subsequent model adaptation study.  Chapter 5 presents the application of the 
Bayesian method for adaptive prediction of tumour volume dynamics during the course of 
radiotherapy. Chapter 6 extends the model for tumour volume to predict TCP. The method is 
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demonstrated through the simulation of virtual patients due to the lack of TCP data of real 
patients. Chapter 7 concludes the thesis with discussion of future research directions. 
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CHAPTER 2 
LITERATURE REVIEW 
 
This chapter starts with the background concepts and overview regarding tumour biology, 
tumour imaging and radiotherapy. In the radiotherapy section, it reviews the different ways of 
radiotherapy and induced cell damage/death, the concept and implementation of radiotherapy 
fractionation, and the development of basic radiobiological models and their clinical 
applications. The subsequent section of this chapter is about the role of mathematical 
modelling in cancer research, previous studies of tumour volume modelling and methods for 
modelling treatment outcomes. Furthermore a review of model calibration methods and 
Bayesian approach will be provided, prior to a summary of this chapter. 
 
2.1 Tumour biology 
Cancer can be defined as a disease in which a group of abnormal cells grow uncontrolled by 
disregarding the normal rules of cell division. Normal cells are constantly subject to signals 
that dictate whether the cell should divide, differentiate or die (Hesketh, 2012). The genes 
transferred from the parents might carry with them an inherent risk or susceptibility to cancer. 
When a normal but risk prone cell is exposed to the external factors such as ultraviolet 
radiation, carcinogenic chemicals, etc., it could undergo a series of genetic mutations and 
transform into a cancerous cell. Mutations cause the cell to evade cell death and grow 
uncontrolled with or without growth signals from the environment (Hesketh, 2012;  Hornberg 
et al., 2006; Doucas & Berry, 2006; Neal & Chb 2006; Enderling & Hahnfeldt, 2011).  
Once the cancer cell is formed, it searches for nutrients from the nearby tissues and 
proliferates rapidly compared to the adjacent normal cells (Roose et al., 2007). The induced 
mutation by the external factors not only enhances the proliferation rate of the cells but also 
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decreases its death rate by down-regulating the tumour suppressor genes (Martins et al., 
2007; Doucas & Berry, 2006).  Over time, this results in the formation of a clump of cells 
known as tumour. Tumour growth is based upon conditions like tumour location, cell type, 
and nutrient supply. Generally, growth is categorised into three stages namely avascular, 
angiogenesis and metastasis (Neal & Chb, 2006; Roose et al., 2007).  
In avascular stage, the tumour growth is localised and nutrients are consumed from the 
nearby tissues (Hahn & Weinberg, 2002; Kiran et al., 2009). At this stage, the tumour is not 
life-threatening. Initially, avascular tumours get adequate nutrients and cancer cells flourish. 
As time proceeds, the avascular tumour growth rate reduces and reaches a saturation size due 
to insufficient nutrition supply to the innermost cells in the tumour. Then, the nutrient-
deficient tumour cells signal the nearby blood vessels about their nutrient requirement leading 
to the second stage called angiogenesis (Hesketh, 2012; Sozzi, 2000; Hornberg et al., 2006).  
 The tumour develops association with the blood vessels in its proximity; subsequently, 
the tumour cells loosen and the cell debris flows through the connected blood vessels. The 
tumour cells can thus migrate from their point of origin to the other parts of the body 
resulting in metastasis (Neal & Chb, 2006). After metastasis, the patient will be left with 
multiple tumours in the body because the migrated cancer cells invade the other parts of the 
body via repetition of the above-mentioned growth phases. At the angiogenesis and 
metastasis stages, the tumour grows very uncontrolled as well as rapidly (Hesketh, 2012; 
Neal & Chb, 2006). Treatment, at this stage, becomes relatively complex. Hence, the early 
detection of the tumour in avascular stage enables cancer cure with higher probability.  
In addition to the above, like any biological cell the tumour cell proliferation cycle is 
defined by two well defined time periods (Vienna, 2010): mitosis (M), where division takes 
place and the period of DNA (deoxyribonucleic acid) synthesis (S). The S and M portions of 
the cell cycle are separated by two periods (gaps) G1 and G2 when, respectively, DNA has 
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not yet been synthesized or has been synthesized but other metabolic processes are taking 
place. The time between successive divisions (mitoses) is called the cell cycle time. In 
general, cells are most radiosensitive in the M and G2 phases, and most resistant in the late S 
phase (Joiner & Kogel, 2009). The cell cycle time of malignant cells is shorter than that of 
some normal tissue cells, but during regeneration after injury normal cells can proliferate. 
 
2.2 Tumour imaging 
Cancer may be difficult to detect, yet usually early detection results in better treatment 
outcomes. Imaging techniques have become an important element of early detection for many 
cancers. In addition to cancer detection, imaging is also important for determining the stage 
(telling how advanced the cancer is) and the precise locations of cancer to guide surgery and 
other cancer treatments, or to check if a cancer has returned. In this section, general 
information of anatomical and biological imaging is presented for completeness. In this 
research, tumour volume data were measured by using CT imaging, which is the most widely 
used form of anatomic imaging technique.  
 
2.2.1 Anatomical imaging 
Anatomical imaging techniques provide regional spatial information. Tumours are 
distinguished from normal tissues based on morphological characteristics, density, size, 
vascularity, and fat and water content. With the introduction of computed tomography (CT) 
(Hounsfield, 1973) and magnetic resonance imaging (MRI) (Mansfield & Maudsley, 1977), 
in the 1970s, cross-sectional imaging of tumours became a reality. This strongly improved 
the accuracy and resolution of tumour imaging compared to plain radiography that had been 
used in the early days of cancer care (Gwyther, 1994).  
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The first CT scanner was built by Godfrey Hounsfield and his colleagues in 1972 
(Cierniak, 2011). In 1979, Hounsfield shared a Nobel Prize with Allan Cormack for their 
scientific contributions to the development of CT technology. X-rays transmitted transversely 
through the patient by an X-ray tube are detected by an array of detectors on the opposite side 
of the tube that rotates around the patient. The detected projection images are reconstructed 
into digital data and then converted to grayscale levels for display. The produced image 
depends (amongst others factors) on the physical characteristics of the imaged tissue, such as 
its density and atomic number. CT may be used to check for many diseases or causes of pain, 
such as a blood clot in the lungs, appendicitis or tissue swelling. The ability to accurately 
diagnose and treat these conditions in a timely manner will, in many cases, improve the 
effectiveness of care (Rubin & Bragg, 2001). 
MRI scans are most often used to look for possible spread of lung cancer to the brain or 
spinal cord. Like CT scans, MRI scans provide detailed images of soft tissues in the body 
(Henkelman, 1992). The difference is that MRI relies on radio waves and strong magnets 
instead of x-rays. The energy from the radio waves is absorbed and then released in a pattern 
formed by the type of body tissue and by certain diseases (Gwyther, 1994). A computer 
translates the pattern into a very detailed image of parts of the body. A contrast material 
called gadolinium is often injected into a vein before the scan to better reveal the details. MRI 
scans take longer than CT (often up to an hour), and are more uncomfortable from the 
patient‘s perspective. The patient needs to lie inside a narrow tube, which is confining and 
can upset people with a fear of enclosed spaces (Henkelman, 1992). 
 
2.2.2 Biological imaging 
Despite their many benefits, anatomical imaging techniques are inherently limited in 
visualising tumour biology as they can only reveal spatial changes in physical properties 
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(Xing et al., 2006). Therefore, many research efforts have recently been invested in cellular 
and molecular biology, computer technology and (bio) chemistry (Apisarnthanarax & Chao, 
2005). This has resulted in advanced biological imaging techniques, mainly based on positron 
emission tomography (PET), single photon emission computed tomography (SPECT), 
functional MRI (fMRI) and magnetic resonance spectroscopic imaging (MRSI), which are 
capable of revealing spatial biology distributions (Wiele, 2006; Verhey et al., 2006). These 
new imaging techniques have also been described as ‗molecular‘ imaging (Weissleder & 
Mahmood, 2001) or ‗functional‘ imaging (Chapman et al., 2003). The general term 
‗biological‘ imaging has been adopted for all techniques that provide complementary 
biological information to the standard anatomical imaging techniques (Ling et al., 2000). 
PET imaging was originally developed by Ter-Pogossian et al. (1976) in the mid-1970s. 
In PET imaging, a positron-emitting radionuclide is tagged to a molecule that is taken up 
selectively by certain types of tissue. Such radiolabelled molecules are called tracers. Each 
emitted positron will annihilate with an electron from the surroundings, resulting in the 
production of two 511 keV annihilation photons emitted in almost opposite directions. These 
coincident photons can be detected externally. After computerized reconstruction, 
tomographic images are obtained. The most frequently used radionuclides are fluorine-18 
(   ), carbon-11 (   ) and oxygen-15 (   ). In SPECT imaging, tomographic images are 
reconstructed based on the external detection of individual photons, emitted by tracers 
labelled with gamma-emitting radionuclides such as technetium-99m        , indium- 11 
       or iodine-123       . Compared to PET, the synthesis of SPECT tracers is generally 
less expensive. Because collimation is required for the detection of single SPECT photons, 
the spatial resolution of PET is better than that of SPECT, but clearly worse than CT or MRI. 
The temporal resolution of both PET and SPECT is poor. Both imaging techniques offer 
reseaonable information for tumour detection (Apisarnthanarax & Chao, 2005), although 
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their sensitivity and specificity are strongly tracer and disease site-dependent, amongst other 
factors (Grégoire, 2004). As they intend to provide complementary information (biological 
versus anatomical), PET or SPECT images differ fundamentally from CT or MRI images 
with regard to their use. 
The most widely used PET tracer is 2-fluoro-2-deoxy-D-glucose (FDG) (Jones, 1996). 
FDG is transported in a cell like glucose itself and is then transformed into FDG-6-phosphate. 
The presence of     in position 2 causes the FDG-6-phosphate to remain un-metabolized 
(Bars, 2006). Therefore, it will accumulate within the cell at a speed proportional to glucose 
need. FDG-PET imaging will thus highlight regions of increased glucose metabolism. 
Tumour cells show an increased rate of glucose consumption, due to an increase of glycolytic 
enzymes and the high number of glucose transporters expressed on malignant cells (Wiele, 
2006). However, in addition to changes in tumour metabolism, FDG uptake is influenced by 
other factors such as tumour burden, blood flow, hypoxia and inflammation. Indeed, hypoxic 
tumours are known to have increased glucose metabolism, as have macrophages that invade 
neoplastic tissues (Price & Jones, 2005). Additionally, some tumour types are not highly 
metabolic, e.g. prostate tumours, or may be masked by high uptake of FDG, e.g. in the brain. 
To overcome these limitations of FDG, it is important to identify the entire tumour profile 
using additional anatomical and biological imaging information.  
Because of their complementarity, multi-modality imaging techniques have been 
developed by combining anatomical and biological imaging modalities. Integrated 
SPECT/CT and PET/CT scanners were introduced clinically in 1998 and 2001, respectively 
(Schulthess, 2005). Using such combined equipment, many of the limitations associated with 
separate CT and PET or SPECT imaging are overcome, like problems with reproducible 
patient positioning and immobilisation, and co-registration of the two image data sets. Multi-
modality imaging provides an anatomical reference frame for the biologically detected 
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lesions, which strongly improves the specificity compared to mono-modality biological 
imaging (Schulthess et al., 2006). Additionally, CT data may be used for the PET or SPECT 
attenuation correction to increase both the imaging accuracy and speed, enabling a more 
efficient use of radiopharmaceuticals as well as an increased patient throughput.  
Apart from their ability to provide anatomical information, MRI techniques are capable 
of visualizing certain biological tumour properties. For instance, fMRI can be used to map 
changes in brain activity, based on the increase in blood flow to the local vasculature that 
accompanies neural activity in the brain (Frahm et al., 2003). One of the advances in fMRI is 
dynamic contrast-enhanced MRI (DCE-MRI), which was developed in the mid-1990s to 
yield information on the microenvironment of tumours and normal tissues, e.g. vascularity, 
blood flow and permeability (Shah et al., 2004). MRSI allows the detection of biochemically 
important compounds other than water or fat molecules. The peaks in the individual MR 
spectra reflect the relative concentration of chemicals within each spatial location. 
Differences in the levels of cellular metabolites between tumours and normal tissues are thus 
exploited. While both the temporal and spatial resolution of MRSI is worse than that of 
conventional MRI, both imaging techniques show a comparable sensitivity. The specificity of 
MRSI is better than that of conventional MRI (Rubin & Bragg, 2001). 
 
2.3 Overview of radiotherapy 
Radiotherapy is the treatment of cancer and other diseases with ionising radiation. Ionising 
radiation deposits energy that injures or destroys cells by damaging their DNA, thus making 
it impossible for them to reproduce. Radiation therapy can damage cancer cells as well as 
normal cells. Therefore, treatment must be carefully planned to minimise side effects. This is 
one of the greatest challenges of radiotherapy: to minimise damage to normal cells through 
the delivery of an adequate dose aimed to destroy tumour cells and spare their normal 
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counterparts. Radiotherapy may be given before surgery to shrink a tumour or after surgery to 
stop the growth of cancer cells that may remain. It can also be given before, during or after 
chemotherapy or hormone treatment to improve overall results (Kaanders et al., 2002; 
Forshier, 2008). 
X-rays, gamma rays and charged particles are types of radiation used for cancer 
treatment. The radiation may be delivered by a machine outside the body (external beam 
radiation) pointing the part of the body to be treated after the careful planning of where the 
generated beams will deposit their energy. Radiotherapy can also be given internally by 
drinking a liquid isotope, delivering it by intravenous injection or by placing a radioactive 
implant directly into or close to a tumour (internal radiation therapy, also called 
brachytherapy). The type of radiation therapy to use depends on the type and size of cancer, 
location, how close the cancer is to normal tissues that are sensitive to radiation, and how far 
into the body the radiation needs to travel. 
Conventional external beam radiation therapy is used in 80% of the radiotherapy cases 
and is delivered, for the most, using linear accelerator (linac) machines. Depending on the 
machine specifications, the energy can be varied with a range of 4-25 MeV (Podgorsak, 
2005). In order to reduce the side effects of the treatment, selective tumour destruction can be 
achieved through enhancing the precision in dose delivery. Different techniques have been 
developed with this aim including: 
 Three dimensional conformal radiotherapy (3-D CRT) 
 Image guided radiation therapy (IGRT) 
 Respiratory gated radiation therapy 
 Adaptive radiotherapy 
 Proton beam therapy 
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One of the most common types of external-beam radiation therapy is called 3- dimensional 
conformal radiation therapy (3D-CRT). Conformal radiotherapy uses a device called a multi-
leaf collimator, which allows the beam of radiation to be shaped properly so that less healthy 
tissue is included in the therapy field. As a result, the healthy surrounding cells and nearby 
structures receive a lower dose of radiation, so the possibility of side effects is reduced.  
In image guided radiotherapy (IGRT), 3-D scans are regularly taken during the treatment. 
The imaging tools interface with the radiation delivery system through hardware or software, 
and allow the optimisation of the accuracy and precision of the radiotherapy by adjusting the 
radiation beam based on the true position of the target tumour and critical organs. This type 
of treatment can work well for tumours in areas of the body that may move during treatment, 
for example due to breathing (Xing et al., 2006; www.cancer.org). Most common types of 
IGRT are intensity modulated radiation therapy (IMRT) and stereotactic ablative 
radiotherapy (SABR). IMRT is an advanced form of 3D therapy. It uses a computer-driven 
machine that moves around the patient as it delivers radiation. Along with shaping the beams 
and aiming them at the tumour from several angles, the intensity (strength) of the beams can 
be adjusted to limit the dose reaching the most sensitive normal tissues. This technique is 
used most often if tumours are near important structures such as the spinal cord. Many major 
hospitals and cancer centres now use IMRT. SABR is sometimes used to treat very early 
stage lung cancers when surgery is not an option due to issues with a patient‘s health or for 
people who do not want surgery. Instead of giving small doses of radiation each day for 
several weeks, SABR uses very focused beams of high-dose radiation given in fewer (usually 
1 to 5) treatments. Several beams are aimed at the tumour from different angles. To target the 
radiation precisely, the patient is put in a specially designed body frame for each treatment. 
This reduces the movement of the lung tumour during breathing. Like other forms of external 
radiation, the treatment itself is painless. Early results with SBRT for smaller lung tumours 
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have been very promising, and it seems to have a low risk of complications. It is also being 
studied for tumours that have spread to other parts of the body, such as the bones or liver 
(Xing et al., 2006). 
Another radiotherapy technique that takes into account the body movement due to 
breathing is the so called respiratory gated radiation therapy. In this technique, the linac 
adapts to the patient‘s breathing pattern, switching the beam off when the tumour moves 
outside the planned treatment volume and switching it back on when it comes back into 
position (Keall et al., 2006). The main application area of this type of radiotherapy is thoracic 
cancers. 
A new technique that compensates for changes in the location of the disease and normal 
tissue during the treatment is the adaptive radiotherapy (ART). This novel approach corrects 
for daily tumour and normal tissue variations through a systematic feedback of measurements 
(Yan et al., 1997). As ART focuses on adapting the target volume being irradiated because of 
changing tumour size, shape and position. Hence it is different from adaptive prediction of 
the tumour volume change under radiotherapy as will be discussed in Chapter 5 of this thesis. 
Another approach for treatment of cancer is proton beam therapy. The rationale for the 
use of protons rather than protons (i.e., X-rays, which have traditionally been used for 
radiotherapy) is the superior dose distribution that can be achieved with protons (Levitt et al., 
2006). Protons and other charged particles deposit little energy in tissue until near the end of 
the proton range, where the residual energy is lost over a short distance, resulting in a steep 
rise in the absorbed dose, known as Bragg peak (Levitt et al., 2006; Paganetti, 2012). The 
Bragg peak is too narrow for practical clinical applications, so for the irradiation of most 
tumours, the beam energy is modulated by superimposing several Bragg peaks of descending 
energies (ranges) and weights to create a region of uniform dose over the depth of the target; 
these extended region of uniform dose are called spread out Bragg peaks. Although Bragg 
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peaks does increase the entrance dose, the proton dose distribution is still characterised by a 
lower dose region in normal tissue proximal to the tumour, a uniform high dose region in the 
tumour. Protons offer the possibility of reducing the volume of normal tissue involved, which 
one might expect to reduce the risk of second malignancies (Levitt et al., 2006; Paganetti, 
2012).   
 
2.3.1 Cell damage/ death due to irradiation 
Radiotherapy causes various types of DNA damage, leading either directly or indirectly 
through the formation of free radicals to the breakage of chemical bonds. Free radicals are 
highly reactive and can induce chemical changes in biologically important molecules like 
DNA. Single-strand or double-strand break in DNA appears to be the basic damage leading 
to biological effects. Specific repair enzymes can successfully repair the vast majority of 
lesions in DNA (Joiner & Kogel, 2009). A few lesions however may not be repaired, and 
may therefore lead to cell death occurs in both tumour and surrounding normal tissues. Cells 
are generally regarded as having been killed by radiation if they have lost reproductive 
integrity. Loss of reproductive integrity can occur by apoptosis, necrosis, mitotic catastrophe 
or by induced senescence. Although all but the last of these mechanisms ultimately results in 
physical loss of the cell this may take a significant time to occur, e.g., mitotic catastrophe 
may not happen until several divisions have taken place. Apoptosis or programmed cell death 
is a strong feature in embryological development and in lymphocyte turnover. Previously, 
this early form of cell death was called inter phase cell death. The characteristics of apoptosis 
(which is non-inflammatory) are in contrast to those of necrosis, typified by cell edema, poor 
staining of nuclei, increase of membrane permeability, shut down of cell metabolism, and an 
accompanying inflammatory response. Senescence or replicative senescence is observed 
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when cells stop dividing, and this differs from the behaviour of stem cells and tumour cells 
which do not show these limitations (Fokas et al., 2009). 
Apoptosis occurs in particular cell types after low doses of irradiation. Reproductive cell 
death is a result of mitotic catastrophe which can occur in the first few cell divisions after 
irradiation, and it occurs with increasing frequency after increasing doses. Cells that fail to 
divide successfully after irradiation can also undergo apoptosis at that stage. Cellular necrosis 
generally occurs after high radiation doses. A rapid fall of cell numbers after irradiation is 
likely to be due to apoptosis but may also occur by mitotic catastrophe in rapidly proliferating 
populations. Whether apoptosis reflects overall cell killing in tumour cell inactivation by 
radiation is currently unresolved and may only be the case for certain types of tumour cells 
(Vienna, 2010). The damage in normal tisse due to irradiation is described in term of early 
and late response of normal tissues to radiotherapy. Because the stem cells are the only cells 
which divide in normal tissues, the earliest effect observed is a deficit in stem cells. Later, the 
loss of stem cells will lead to a deficit in differentiated cells, causing the observed clinical 
reactions. The early reactions are seen during the first days or weeks after irradiation (for 
example diarrhoea or acute mucositis). They are temporary because the cell deficit is 
compensated for by the repopulation of stem cells, and subsequently of differentiated cells. 
Late reactions due to damage to the late-reacting tissues, for instance blood vessel damage, 
fibrosis, telangiectasia, etc., may be seen after months or years. Damage to these late reacting 
normal tissues is poorly repaired and is responsible for most severe complications of 
radiotherapy (Vienna, 2010; Forshier, 2008; Dale & Fernandez, 2005; Fokas et al., 2009). 
 
2.3.2 Radiotherapy fractionation 
In radiation therapy the overall patient outcome can be substantially improved by 
fractionating radiation treatments, that is, the total radiation dose is delivered through a 
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number of fractions (e.g. 64 Gy is delivered in 32 fractions, resulting in 2 Gy per fraction). 
Many of the underlying biological effects occurring during fractionated radiation treatment 
have been identified, and the improvement may be explained in terms of the biological 
response of tissue. The basis of fractionation is rooted in four primary biological factors 
called ―four Rs‖: repair, repopulation, redistribution or reassortment and reoxygenation (Supe 
et al., 2006; Clark, 2012; Jones & Dale, 1999). 
 Repair of sublethal DNA damage by normal cells: Radiation damage to cancer cells is 
the result of DNA strand breaks. Normal cells have better DNA repair machinery. 
Fractionated treatment preferentially allows normal cells to repair sublethal DNA 
damage. 
 Repopulation of normal healthy cells: The time interval between radiation fractions 
allows normal cells to grow, divide, and therefore continue normal function at the 
level of tissues and organs. 
 Reassortment of tumour cells into more radiosensitive phases of the cell cycle: Cancer 
cells have varying sensitivity to radiation depending on their current phase of the cell 
cycle. In between treatments, some proportion of cells will cycle into a more sensitive 
phase, rendering them more susceptible to radiation damage (Jones & Dale, 1999). 
 Reoxygenation of tumour cells: The majority of radiation damage to the DNA of 
cancer cells occurs through a free radical mechanism that is enhanced by oxygen. The 
time interval between fractions allows additional perfusion of oxygen into areas of the 
tumour that tend to have low levels of oxygen, leading to an enhanced effect of 
radiation in the tumour. In short, fractionation is used to optimize radiotherapy 
treatment for curing cancer and preventing side effects. 
The purpose of fractionation is to exploit the the difference in the response of normal and 
tumour cells to radiation. The different types of radiotherapy fractions will be briefly 
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discussed here. Conventional fractionation practices division of dose into multiple fractions 
spares normal tissues through repair of sublethal damage between dose fractions and 
repopulation of cells. The former is greater for late reacting tissues and the latter for early 
reacting tissues (Steel, 2002; Hall, 2000; Nias, 1998).  Fractionation increases tumour 
damage through reoxygenation and redistribution of tumour cells. A balance is achieved 
between the response of tumour and early and late reacting normal tissues, so that small doses 
per fraction spare late reactions preferentially, and a reasonable schedule duration allows 
regeneration of early reacting tissues and tumour reoxygenation to likely occur. The 
conventional fractionation is based on the application of daily doses of 2    five fractions per 
week and a total treatment time of several weeks (Steel, 2002; Hall, 2000; Nias, 1998). This 
regimen reflects the practical aspects of dose delivery to a patient, successful outcome of 
patient treatments and convenience to the staff delivering the treatment. Other fractionation 
schemes are being studied with the aim of improving the therapeutic ratio (maximisation of 
probability of tumour control and minimisation of probability of normal tissue 
complications). Some of these are hyperfractionation, accelerated fractionation 
(hypofractionation) and CHART (continuous hyperfractionated accelerated radiation 
therapy): 
 Hyperfractionation uses more than one fraction per day with a smaller dose per 
fraction (<1.8 Gy) to reduce long term complications and to allow delivery of higher 
total tumour dose. This exploits a cell line with a high α/β value as it is relatively 
insensitive to changes in fraction size, and this reduces late effects with only a slight 
increase in early effects (Forshier 2008; Dale & Fernandez, 2005; Fokas et al., 2009; 
McAneney & O‘Rourke, 2007). 
 Accelerated fractionation reduces the overall treatment time, minimizing tumour cell 
repopulation during the course of treatment and is therefore suited to cell lines with a 
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low α/β value. It is intended to reduce repopulation in rapidly proliferating tumours, 
but as the number and dose per fraction is unaltered, late effects are unchanged 
(Steel, 2002). 
 CHART is an experimental programme used with three fractions per day for 12 
continuous days (Steel, 2002; Hall, 2000; Nias, 1998). 
 
2.3.3 Cell survival curve and radiobiological models 
A cell survival curve describes the relationship between the surviving fraction of cells and the 
absorbed dose. Cell survival as a function of radiation dose is graphically represented by 
plotting the surviving fraction on a logarithmic scale on the ordinate against dose on a linear 
scale on the abscissa. Cell surviving curves data are usually from in vitro cell line 
experiments, thus they are useful for clinical response but may not exactly describe the 
complexity in clinical situations. The type of radiation influences the shape of the cell 
survival curve. Densely ionizing radiations exhibit a cell survival curve that is almost an 
exponential function of dose, shown by an almost straight line on the log–linear plot as 
presented in Fig. 2.1(a). For sparsely ionizing radiation, however, the curves show an initial 
slope followed by a shoulder region and then become nearly straight at higher doses as shown 
in Fig. 2.1 (b). 
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Fig. 2.1 Cell survival curves for high LET (linear energy transfer) radiation and low LET 
radiation (Steel, 2002; Hall, 2000). (a) the multi-target model; (b) the linear quadratic model 
 
Factors that make cells less radiosensitive are: removal of oxygen to create a hypoxic state, 
the addition of chemical radical scavengers, the use of low dose rates or multi-fractionated 
irradiation, and cells synchronized in the late S phase of the cell cycle. Several mathematical 
methods of varying degrees of complexity have been developed to define the shape of cell 
survival curves, all based on the concept of the random nature of energy deposition by 
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radiation. The linear quadratic and multi-target models are used to describe the cell survival 
curves for low and high dose of irradiation per fraction respectively.  
Mathematically multi-target model is presented as:  
     ( 
 
  
 
  
  
)                                                                               
The multi-target model described the slope of the survival curve by    (the dose to reduce 
survival to 37% of its value at any point on the final near exponential portion of the curve) 
and the extrapolation number n (the point of intersection of the slope on the log survival 
axis).    is the quasi-threshold dose. This model could be used when radiotherapy dose per 
fraction is high (e.g. dose      (Park et al., 2008).  Further details regarding multi-target 
model will be discussed in Chapter 4.  
The linear-quadratic (LQ) model has been a useful tool for understanding the radiation 
survival response for a tumour (Fowler, 2006) and has gained relatively widespread 
acceptance among radiobiologists and clinicians (McAneney & O‘Rourke, 2007). It has been 
used to investigate different schedules of radiation treatment planning to study how these 
may be affected by different tumour repopulation kinetics between treatments. 
It states that for external beam radiotherapy, the surviving fraction   is given by 
                                                                                 (2.2) 
where D ( y) is radiation dose and α        and β        are the radiobiological cell 
survival parameters dependent on tissue type within the volume being treated. These 
parameters are biologically interpreted as single and double strand breaks in DNA  
respectively (Sach et al., 1997). 
The typical range for α/β values can range from 3 to 10  y according to (Lebioda et al., 
2007). However, wide range for α/β was also quoted in the literature, for example as low as 1 
 y in the case of prostate cancer and as high as 20  y in the case of advanced head and neck 
 
 
24 
 
cancer (Dale & Carabe, 2005; McAneney & O‘Rourke, 2007). Typically, late responding 
tissues correspond to low α/β values and have a high repair capacity, while acute responding 
tissues have high α/β values and a low repair capacity. Acute responding tissues have fast 
cellular turnover and therefore show signs of radiation induced damage to normal tissue days 
to weeks after exposure. This can be explained due to the short lifespan of their mature cells. 
By comparison late responding tissues show effects months to years later because they have a 
low level of cellular turnover and the interval between cell divisions is long giving the cells 
an opportunity to repair radiobiological damage (Vienna, 2010). In contrast, the response by 
acute responding tissue is influenced by (i) fractionation, but to a lesser degree, and (ii) the 
overall treatment time (Vienna, 2010).   Advances in the treatment schedules have resulted 
from taking account of the particular radiobiological cell survival parameters (α/β) involved. 
 
2.3.4 Clinical treatment outcomes 
Recent years have witnessed burgeoning interest in using radiobiological models to assess 
radiation therapy patient treatment plans in order to identify the ‗optimal‘ plan or at least 
personalize the patient‘s plan (Brahme, 1999; Deasy et al., 2002; Li, 2011). This interest has 
been driven by technological advances in intensity modulated radiotherapy (IMRT) that have 
allowed the delivery of very complex shaped dose distributions almost unimaginable a 
decade ago. Nevertheless, these technological advances did not translate into similar 
significant improvements in cancer patient survival rates (Begg et al., 2011; Fraass and 
Moran, 2012). By part, this has been hampered by a lack of current radiobiological model‘s 
ability to predict accurately, at the time of treatment planning or during the treatment, the 
individual outcomes associated with such complex dose distributions and delivery time 
sequences. It is believed that appropriate prediction of treatment outcomes would provide 
clinicians with better tools for informed decision-making about designing more effective 
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treatment plans that are tailored to maximize benefit and reduce side effects for individual 
patients (Halperin et al., 2008).  
Many mathematical models have been developed to help predict the outcome of a given 
radiation treatment. One such model is the tumour control probability (TCP). The TCP is a 
measure of the probability of tumour cell eradication and it can be used to compare the 
expected success of different treatment protocols (Gong et al., 2011). Hence, TCP and normal 
tissue complication probability (NTCP) are two primary metrics used to determine 
radiotherapy dose and schedule (South et al., 2009; Steel, 2002; Webb, 2001). TCP/NTCP 
models could be used during the consultation period as a guide for ranking treatment options 
(Armstrong et al., 2005; Weinstein et al., 2001). TCP/ NTCP are highly important for the 
prediction of radiotherapy outcomes.  In this research, we focus on TCP prediction. As some 
studies are already done to determine TCP after the treatment to address radiotherapy dose 
issues (South et al., 2008, 2009; Web & Nahum, 1993; Zaider & Hanin, 2011; El Naqa et al., 
2010; Warkentin et al., 2004), but no research has been done for TCP prediction during the 
treatment for individual patient that helps clinicians for updating planning and scheduling to 
get better clinical treatment outcome. Hence in this research, adaptive modelling approach for 
TCP prediction will be used to address the issue regarding diagnose of treatment outcomes 
during the treatment. The scope, methodology and practical application of personalised 
adaptive TCP prediction approach is presented in Chapter 6. 
 
2.4 Overview of mathematical cancer modelling 
In this section, the role and importance of mathematical modelling in the area of tumour 
research are presented. Moreover, homogenous and heterogeneous tumour growth models are 
discussed. Notably, the previous studies regarding tumour volume modelling are presented 
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that highlighted the gaps in existing studies and provided a direction for the potential of this 
research work.  
 
2.4.1 Role of modelling in tumour research 
The subject of tumour modelling research is to improve the current treatment and the 
prevention through a deep understanding of tumour patho-physiology (Gerisch & Chaplain, 
2008). The data produced in quantity of tumour biologists and clinical oncologists is 
suggested to be arranged on the conceptual frame work. Therefore, the mathematical 
modelling and bio-computation can be support to better understand the overall tumour 
appearance and its treatment. There are many factors limiting the development of traditional 
clinical and biological experiments. The equipment precisions, human error and inability to 
distinguish the various mechanisms may result in incorrect data and wrong treatment 
(Gerisch & Chaplain, 2008).  
 
2.4.2 Tumour growth models 
The growth of tumour is classified as follows: homogeneous and heterogeneous growth of 
tumours. The ordinary differential equation (ODE) and partial differential equation (PDE) 
models are developed for the growth of solid tumour. The ODE models view cancer as a 
population of cells and study how the population evolves. The PDE models are spatially 
structured. They allow to make a dynamic description of spatial variations in the system 
(Byrne, 2003; Martins et al., 2007; Ribba et al., 2006; McAneney & O‘Rourke, 2007; Ward 
& King, 1997; Roose et al., 2007; Lloyd et al., 2008; Macklin et al. 2009). 
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2.4.2.1 Homogenous growth of tumour 
In homogenous growth model, all tumour cells were assumed to be identical. As generally 
tumour growth models are expressed by exponential growth, logistic growth and Gompertz 
model. In exponential growth model, tumour volume changes exponentially over time, while 
logistic and Gompertz model can capture a decrease in tumour growth rate over time. The 
Gompertz equation assumes an exponentially decreasing growth rate, whereas logistic 
equation instead assumes that the growth rate falls off linearly with the size, until it becomes 
equal to zero when it reaches the carrying capacity (Gerlee, 2013). Mathematically Gompertz 
tumour growth model is presented as (Gerlee, 2013); 
  
  
     (
 
 
)                                                                                                                              
                                                with              
where   represents the carrying capacity of the population,   denotes rate of proliferation of 
cancer volume,   symbolizes tumour volume and    represents the initial value of the 
tumour volume and   stands for time. In logistic growth model, the initial stage of growth is 
approximately exponential; then, as saturation begins, the growth slows, and at maturity, 
growth stops (Byrne, 2003; Gerlee, 2013; Ribba et al., 2006). However, the mathematical 
formulation for simple to complex models regarding exponential and logistic growth will be 
discussed in the next chapter.    
 
2.4.2.2 Heterogenous growth of tumour 
In reality, tumour is heterogeneous consisting of many different types of cells. For example, 
vascular tumours growing in vivo may contain blood vessels that supply nutrients to the 
tumour, extracellular matrix and immune cells such as macrophages. In addition, the tumour 
cell population may contain functionally distinct subpopulations. These sub populations, 
which are often caused by genetic mutations, may be characterised by different proliferation 
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and death rates and different responses to environmental conditions. By considering the 
proliferation rates of tumour cells at increasing distances from a blood vessel, we can 
appreciate a different type of heterogeneity within solid tumours which is based upon local 
environmental conditions (Byrne, 2003; Martins et al., 2007; Ribba et al., 2006; McAneney 
& O‘Rourke, 2007; Ward & King, 1997). 
Cells adjacent to the blood vessel have an abundant supply of nutrient and, hence, 
proliferate freely. As the distance from the vessel increases the local nutrient concentration 
falls since it is being progressively consumed as it diffuses away from the blood vessel. 
Eventually a point is reached at which the nutrient concentration becomes so low that the 
tumour cells there are unable to proliferate, although they have sufficient nutrient to remain 
alive. These cells are termed quiescent. At greater distances from the vessel, the nutrient 
concentration may become so low that the quiescent cells are unable to stay alive: they die 
due to nutrient deprivation, forming a region of necrotic cellular debris. Thus we may 
characterise tumour cells as (a) proliferating, (b) quiescent, and (c) necrotic or dead as shown 
in Fig. 2.2. Typically, all three cell types will be present within a vascular tumour and a well-
developed avascular tumour (Byrne, 2003; Martins et al., 2007; Ribba et al., 2006, 
McAneney & O‘Rourke, 2007; Ward & King, 1997). 
                                                                                                                                                                                                                                                                                   
                                                                          Proliferating zone 
                                                                                                                                  Quiescent layer  
                                                                                                                                    Necrotic core 
  
   
 
                                                                                                                                
                                                                                              
Fig. 2.2 Three layer structure of a tumour spheroid (adapted from Roose et al., 2007)  
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A mathematical model has been developed to consider the three cell types separately. We 
denote by P(t) the number of proliferating cells at time t, Q(t) the number of quiescent cells, 
D(t) the number of dead or necrotic cells, and T(t) = P(t) +Q(t) + D(t) the total number of 
tumour cells. In mathematical model we will see how cells may change from one state to 
another, how new cells are produced (proliferation) and how dead cells are degraded (Byrne, 
2003; Roose et al., 2007; Lloyd et al., 2008). In the light of all above assumption, the 
mathematical model may be written as follows:  
  
  
 (           )                                                                                             
  
  
      (       )                                                                                                    
  
  
                                                                                                                      
initial values, 
 (0) =   ,        (0) =  ,    (0) =                                                                                    (2.7) 
The functions                    and     in equations (2.4) to (2.6) represent the rates at 
which proliferating cells produce new cells, proliferating cells become dead, quiescent cells 
start proliferating, quiescent cells goes dead and cells stop proliferating and become quiescent 
(Byrne, 2003; Ribba et al., 2006). Where   stands for the decay rate of the necrotic cellular 
material. If we considered spatial effects in tumour growth, then our model becomes more 
complex and mathematically this type of model is presented by partial differential equation.  
The purpose of mathematical models is to identify key mechanisms that underlie 
dynamics and events at every scale of interest. Hence, the ultimate aims of cancer models, are 
to enlighten our concept of the carcinogenesis process and to assist in the designing of 
treatment protocols that can reduce mortality and improve patient quality of life (Enderling et 
al., 2010). The development of quantitative predictive models (based on sound biological 
evidence and parameterized by biological data) will no doubt have a positive impact on 
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patients suffering from diseases such as cancer through improved clinical treatment 
(Chaplain, 2011). Further, the previous studies regarding tumour-volume modelling is 
already expressed in first chapter. However, practical application of tumour-volume 
modelling approach will be presented in next chapter. 
 
2.4.3 Previous studies of modelling tumour volume change in response to radiotherapy  
Mathematical modelling of tumour progression and response to radiotherapy has been well 
reported (Byrne, 2003; Deisboeck et al., 2009). However in the past, very limited research 
was focused on modelling tumour response during treatment, partly because of the lack of in-
treatment measurements.  
In existing studies, some of models have been developed in an attempt to describe and 
predict how tumour volume changes over time. Some of these modelling studies were 
simulation-based, aiming to explore how mathematical models can be used to optimise the 
treatment dose and dose schedule for better outcome (Chen et al., 2012; Dionysiou et al., 
2006; Harrold & Parker, 2009; Kiran et al., 2010; South et al., 2008). Others are more 
focused on exploring the various biological and treatment-related mechanisms that should be 
included in the model, in order to better describe the observed data. For example, it was 
shown that a simple mathematical model incorporating the effects of radiotherapy and 
chemotherapy can provide excellent agreement with clinical trials, in terms of population 
patient survival (Barazzuol et al., 2010).  
In addition, Swanson and co-workers (Harpold et al., 2007; Rockne et al., 2009, 2010) 
calibrated a model of partial differential equations MRI scans of brain tumours; the scans 
were taken months apart and may not be frequent enough to accurately estimate the model 
parameters. Furthermore, in their work the volume was only measured before and after, not 
during the treatment. Similar studies were reported for radiotherapy of cervical cancer 
 
 
31 
 
(Huang et al., 2010) and stereotactic radiotherapy of lung cancer (Chvetsov et al., 2008), 
where the tumour volume was also measured pre- and post-treatment. In contrast, modelling 
in-treatment volume dynamics is less common. Based on frequent CT scans, Chvetsov et al. 
(2009) developed a radiobiological model detailing the dynamics of four cell populations, 
which may be more complex than necessary since tumour volume is the only information 
available. An empirical regression model was presented in (Seibert et al., 2007), but it does 
not have a radiobiology basis.  
Another interesting work, though applied to chemotherapy, was the modelling of liver 
metastatic disease (Filipovic et al., 2014). These gaps in previous studies helped to establish 
the useful modelling of tumour response to radiotherapy during the treatment. The detail of 
motivation and objectives of this research have been discussed in chapter 1.  
 
2.5 Model calibration 
In general, to develop a model, we postulate a mathematical form, guided by physical insight, 
and then perform a number of experiments to determine the choice of parameters that best 
matches the model behaviour to that observed in the set of experiments. This procedure of 
model proposition and comparison to experiment generally must be repeated iteratively until 
the model is deemed to be sufficiently reliable for the purpose at hand. The problem of 
drawing conclusions from data is known as statistical inference, and in particular, our focus 
here is upon parameter estimation. In this research, powerful Bayesian framework for 
statistics is used, which provides a coherent approach to statistical inference and a procedure 
for making optimal decisions in the presence of uncertainty (Kenneth, 2007). In here, the 
importance of parameter estimation and Bayesian statistics (maximum posterior estimation) 
will be discussed. 
 
 
 
32 
 
2.5.1 Parameter estimation 
Parameter estimation is one of the steps involved in the formulation and validation of a 
mathematical model that describes a process of interest. Parameter estimation refers to the 
process of obtaining values of the parameters from the matching of the model-based 
calculated values to the set of measurements (data). This is the classic parameter estimation 
or model fitting problem and it should be distinguished from the identification problem. The 
latter involves the development of a model from input/output data only (Peter 2000). This 
case arises when there is no a priori information about the form of the model i.e. it is a black 
box. When the model equations are linear functions of the parameters the problem is called 
linear estimation.  
Nonlinear estimation refers to the more general and most frequently encountered 
situation where the model equations are nonlinear functions of the parameters. Parameter 
estimation and identification are an essential step in the development of mathematical models 
that describe the behaviour of physical processes. Our focus will be on the estimation of 
adjustable parameters in nonlinear models described by ordinary differential equations (Peter 
2000). 
The best parameters are estimated in order to be used in the model for predictive 
purposes at other conditions where the model is called to describe process behaviour. The 
unknown model parameters will be obtained by minimizing a suitable objective function. The 
objective function is a measure of the discrepancy or the departure of the data from the model 
i.e., the lack of fit. In parameter estimation, the general problem we have to solve is: Given 
the structure of the model (i.e. the governing model equations) and a set of measured data 
points, the problem is to find the unknown model parameters so that the values calculated by 
the model match the data in some optimal manner (e.g., by minimizing the sum of squares of 
errors) (Peter 2000). 
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Parameter estimation plays a critical role in accurately describing system behaviour 
through mathematical models. Model examples include statistical probability distribution 
functions, parametric dynamic models, and data-based Simulink models. As a general 
purpose computational tool, Matlab provides a broad range of parameter estimation 
capabilities (Brian 2010) and is used in this research. 
 
2.5.2 General problem formulation 
The basic parameter estimation problem involves fitting the parameters of a proposed model 
to agree with the observed behaviour of a system. We assume that, in any particular 
measurement of the system behaviour, there is some set of predictor variables          
that fully determines the behaviour of the system (in the absence of any random noise or 
error). For each tumour volume measurement, we measure some set of response variables 
         If L=1, we have single-response data and if L>1, multi-response data (kenneth, 
2007). We write these predictor and response vectors in row form (Kenneth, 2007), 
     =[          ]      
      [                                                   (2.8) 
Where       represents the predictor variable   and      stands for response variable    We 
propose a mathematical relation, which maps the predictors       to the responses     , that 
involves a set of adjustable model parameters     , whose values we wish to estimate from 
the measured response data. Let us say that we have a set of n tumour volume measurements, 
in which for tumour volume data j = 1, 2, ...,n,      is the row vector of predictor variables 
and the row vector of measured  response data is      . For each tumour volume data, we 
have a model prediction of the response 
 ̂      = f(      )                                                            (2.9) 
The basic parameter estimation problem is: given a proposed model f(      ), how do we 
choose   such that the model predictions  ̂       agree most closely to the observations         
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Of course, we need to ask how close enough is to accept the model. Given the data at hand, 
which generally include some uncontrolled random errors, how do we estimate the accuracy 
with which we have estimated  ? Here we use Bayesian statistics, a framework for 
describing how our uncertainty in the values of the parameter changes by doing the 
experiments. Before doing the tumour volume measurement, we characterize our knowledge 
about     which we treat as a random vector by a prior probability density p     If we have 
accurate prior knowledge, this distribution is sharply peaked; if not, it is diffuse. After 
obtaining new data {    } from the GTV measurement, we use the rules of Bayesian analysis 
to compute a posterior density  ( |{    })  that describes our new uncertainty after taking 
into account the additional. With this posterior, we can test hypotheses, from confidence 
(credible) intervals, and make rational decisions based on uncertainty in   using numerical 
simulation (Kenneth, 2007). 
The formation of confidence intervals, selection of parameter estimation rules, etc. In the 
sampling approach are not as direct, and sometimes not as well behaved, as those of Bayesian 
statistics (Kenneth, 2007). A large fraction of the statistics community has been resistant to 
the Bayesian paradigm, but this situation is changing and the modern practise of statistics is 
increasingly Bayesian. Thus here, we provide an overview of Bayesian statistics, as we use 
this powerful tool in our project for model adaptation.  
 
2.5.3 Methods for Parameter estimation 
2.5.3.1 Maximum likelihood 
The inference of the joint probability distribution of   can be achieved in a number of ways. 
One approach is based on the likelihood. The likelihood function, L, is defined as the 
probability of realizing the data, y, given the value of the parameters (Bishop, 2009). 
      =p  |                                                             (2.10) 
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The method of maximum likelihood (ML) estimates the parameters by locating the 
supremum of the function        within the space of    based on the rationale that the 
parameters are chosen to maximize the probability of observing the data. The inference 
approach based on maximum likelihood has two limitations. First, maximum likelihood 
estimation does not take into account prior knowledge about the possible values of the 
parameters before observing the data (Kenneth, 2007).  In many applications, through an 
understanding of the physical system of interest, it is known that some values of the model 
parameters are not feasible. This aspect is not considered in maximum likelihood estimation.  
Secondly, the likelihood function on its own does not restrict the number of parameters 
included within a model to fit the data. It is well recognized that a data set comprising n 
observations can always be exactly described in terms of a model with n parameters. This 
behaviour raises serious issues with respect to over-fitting, whereby the parameters estimated 
from the training data generalize extremely poorly to new unseen data, seriously limiting the 
applicability of the model for predictive purposes (Bishop, 2009). 
A more serious issue with maximum likelihood is that, it has been observed that over-
fitting emerges as an issue not only as a result of the number of parameters fitted being large, 
but also with respect to the magnitude of the parameters. 
Despite the success of these modified maximum likelihood estimation approaches, it can 
be argued that there exist more intuitive ways in which the prior knowledge about the model 
can be included, thereby addressing the over-fitting issue (Bishop, 2009). 
 
2.5.3.2 Least squares estimation 
The method of least squares is about estimating parameters by minimizing the squared 
discrepancies between observed data, on the one hand, and their expected values on the other 
(Strejc, 1980; Everitt & Howell, 2005;  Ding, 2013; Zhu et al., 2005; Johnson & Faont, 
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1992).  Here, we present the relation of least square estimation with maximum likelihood 
estmation.  
Relation to maximum likelihood estimation 
In maximum likelihood estimation we seek the parameter values that are most likely to have 
produced the data. On the other hand, in least square estimation, we seek the parameter 
values that provide the most accurate description of the data, measured in terms of how 
closely the model fits the data under the square-loss function. Formally, in least square 
estimation, the sum of squares error (SSE) between observations and predictions is 
minimized. As in maximum likelihood, finding the parameter values that minimize SSE 
generally requires use of a non-linear optimization algorithm. Minimization of least square 
estimation is also subject to the local minima problem, especially when the model is non-
linear with respect to its parameters (Myung, 2003). In general, least square estimates tend to 
differ from maximum likelihood estimates, especially for data that are not normally 
distributed. When this occurs, maximum likelihood estimation should be preferred to least 
square estimation, unless the probability density function is unknown or difficult to obtain in 
an easily computable form. There is a situation, however, in which the two methods intersect. 
This is when observations are independent of one another and are normally distributed with a 
constant variance. In this case, maximization of the log-likelihood is equivalent to 
minimization of SSE, and therefore, the same parameter values are obtained under either 
maximum likelihood estimation or least square estimation (Myung, 2003). 
 
2.5.4 Bayesian statistics 
2.5.4.1 The Bayesian view of statistical inference 
In practise, it is insufficiently merely to identify the values of the parameters that minimize 
the sum of squared errors. Here, we address this topic with Bayesian statistics, which 
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describes how our uncertainty in the parameter values is changed by doing the experiments. 
Bayesian statistics is based upon manipulation of the probability p  |   that the model has a 
parameter vector  , given a set of measured response data y (Kenneth, 2007). The use of a 
Bayesian framework is justified in situations where the task is purely data driven, such as 
probability density estimation (Kennedy & O'Hagan, 2001). 
The generic procedure for the implementation of probabilistic inference is as follows: 
1- Formulate a full probability model, that is, the joint probability distribution for all 
      the quantities within a problem, denoted by the vector    
2- Calculate and interpret the joint probability distribution of the quantities. 
3- Evaluate the quality of the model. 
4- Use the model to predict future quantities (model prediction) that can then be used for 
decision making repeat step 3 until convergence is reached.      
Models can be established based on the understanding of physical systems, such as the 
representation of dynamic system by differential equations, they can also be data driven, such 
as the inference of some quantities based on the observation of other quantities (regression 
analysis), or the estimation of the probability distribution function from observed data 
(Kennedy & O'Hagan, 2001). 
 
2.5.4.2 Bayes’ theorem 
The deficiencies in the likelihood framework are addressed in a simple and direct way 
through a Bayesian framework, which is based on Bayes' theorem (Bishop, 2009). 
   |    
   |      
∫    |        
  
     |      
    
                                        
where   ( ) is the prior probability which summarizes the knowledge about the parameter 
values before data becomes available. By noting that the normalizing factor,  (y), does not 
depend on the parameters, Bayes' theorem states that the joint posterior distribution of the 
 
 
38 
 
parameters,    |  , is proportional to the product of the prior distribution and the likelihood 
function. Bayes' theorem therefore provides a methodology for summarizing the information 
about the parameters, and it allows the prior knowledge to be updated in the light of the 
available data. This process is naturally sequential, since the posterior distribution obtained at 
one stage of the analysis acts as the prior in the next stage when more data becomes available 
(Bishop, 2009). 
 
2.5.4.3 Prior distribution 
The selection of the prior distribution plays an important role in Bayesian data analysis. In 
general, the prior distribution should be more diffuse than the likelihood function, reflecting 
the belief that the observed data contribute more significantly to the estimation of model 
parameters. The prior can be selected according to the availability of subjective knowledge 
about the model parameters. It can also be selected such that the resultant posterior 
distribution has a standard form (e.g. Gaussian distribution), and hence estimation of the 
model parameters can be easily undertaken. In real problems, one must consider both these 
issues to identify prior distributions that are most appropriate for the application under 
consideration (Kenneth, 2007). 
 
2.5.4.4 Maximising a posteriori 
The objective of maximum a posterior (MAP) estimation is to find the most probable values 
for a set of parameters by maximizing the posterior distribution, analogous to maximum 
likelihood estimation. The maximum value can be found by implementing one of a range of 
optimization approaches, for example, Gauss-Newton, conjugate gradient, conditional 
maximization, and non-linear Gauss-Seidel iteration (Givens & Jennifer, 2005). Bayesian 
methods have been widely used in statistical inference. Their applications range from simple 
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parameter estimation to the regularization of ill-posed inverse problems.  The use of Bayesian 
methods has also received attention in other settings such as the estimation of uncertainties in 
dose distribution in inverse treatment planning (Borman, 2009).  
The MAP method is used for the point estimation of model parameters which maximize 
the posterior distribution. To achieve future prediction (model adaptation), these estimated 
values (true values) of parameters are used in the model. The practical application of 
maximum a posterior (MAP) estimation in this research work will be discussed in later 
chapters. 
 
2.6 Summary 
In this chapter, an overview and background concepts was provided with the focus on tumour 
biology, radiobiology, tumour modelling, model calibration, clinical treatment outcome and 
Bayesian model adaptation. In tumour biology, the study was focussed on what is tumour and 
how it can spread and at what stage tumour become more malignant and further it discussed 
about cell cycle of tumour. In radiobiology, firstly it covers the role of imaging modalities 
and radiotherapy. Secondly it covers how tumour cell get damage/ death and moreover it 
covers the areas of tumour cells and normal tissue cells response to radiotherapy, and further 
to know abstractly about significance of radiotherapy fractionation.  
Thirdly the attention was made to understand historical development of clinical 
applications of radiobiological modelling using the LQ model. However a lot of attention had 
been made on tumour modelling due to its importance in our research work. In tumour 
modelling, we learnt about the previous studies regarding tumour-volume modelling and also 
found out the gape in existing tumour-volume modelling research, furthermore found a 
direction to solve this issue. Additionally we discussed about previous studies, gaps in 
tumour volume modelling and importance regarding clinical treatment outcome and finally 
 
 
40 
 
found a direction to address this issue, because clinical treatment outcome can be used in 
prognosis purposes for treatment efficacy.  
Besides, critical and conceptual analysis was focussed on parameter estimation and 
Bayesian model adaptation. As parameter estimation and MAP are used in adaptive GTV and 
TCP prediction. The chapter primarily served as a literature review of relevant tumour 
modelling approaches, Bayesian adaptive modelling method and TCP prediction that will be 
applied in subsequent chapters. 
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CHAPTER 3 
CLINICAL DATA  
 
This chapter describes the two data sets that were used to support the modelling studies. It 
should be noted that the author participated in the planning and discussion for collecting the 
first data set (referred to as ―SABR data‖ for brevity) from the Royal Surrey County Hospital; 
the actual data collection was conducted by a team of radiotherapy physicists (Dr Christopher 
South and Ms Laia Humbert-Vidan). The second data set (referred to as ―tomotherapy data‖) 
was kindly provided by the London Regional Cancer Program, Ontario, Canada. 
 
3.1 The SABR data 
Data from 18 patients with stage 1 non-small cell lung cancer (NSCLC), treated with SABR at 
the Royal Surrey County Hospital, Guildford, UK using the Varian RapidArc® technology, 
were collected in 2013-2014. High set up accuracy for SABR patients was achieved with daily 
online imaging. A low dose thorax cone-beam CT (CBCT, 512x512 reconstruction volume, 2.5 
mm slice thickness, half bow tie filter) was acquired pre- and post-delivery of each treatment 
fraction and matched to the averaged 4DCT (4-dimensional computed tomography) image used 
for treatment planning. The patient was repositioned for set up errors larger than 5 mm and 
couch shifts are only applied for corrections larger than 2 mm. Further, target dose escalation 
from the conventional 2 Gy per fraction to up to 18 Gy per fraction with acceptable doses to 
surrounding normal tissues has been possible, thanks to advanced image guidance and 
treatment delivery techniques (Jain et al., 2013). These have provided a higher patient set up 
accuracy and improved radiation dose conformity leading to reduced target volume margins 
and high dose gradients outside the target volume (Brown et al., 2014). 
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Contouring of the GTV was carried out by an experienced medical physicist on the first 
treatment fraction CBCT image, based on the GTV contoured by the clinician on the planning 
4DCT image. It would be desired to have the clinician to contour the tumour; however due to 
resource constraints, this was not feasible. In addition, relying on manual contouring by a busy 
(and expensive) clinician will substantially restrict the practical value of the model. It was 
essential that the contouring of tumour on consecutive CBCTs be as objective as possible. In 
order to achieve this, the Hounsfield unit (HU) range of the Eclipse automated segmentation 
tool (Eclipse V10.0, Varian medical system) for the CBCT GTV was first adjusted to match 
the volume of the clinician-outlined GTV. A visual check was made to ensure that the resulting 
CBCT contour was geometrically and anatomically comparable to the original GTV. The HU 
range used for the first CBCT was then applied to the subsequent CBCT images for the rest of 
the treatment fractions and the resulting volume measurements recorded as the GTV size for 
each treatment fraction. Minor manual adjustments to the contouring were required where the 
auto-contour volume of interest clearly contained uninvolved high-density structures such as 
chest wall and rib. Patients for whom image artefact or anatomical location made this 
distinction ambiguous (e.g. tumours close to diaphragm) were excluded from the study. To 
assess inter-observer measurement variability, a second physicist independently repeated the 
contouring of selected patients, and the average variability was 3.7% of the measured GTV. As 
an example, Fig. 3.1 illustrates Patient 5‘s planning CT and subsequent CBCT images. 
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a) Planning CT (GTV=28.65   )    b) CBCT 1 (GTV=28.69   ) 
    
c) CBCT 2 (GTV=26.83   )    d) CBCT 3 (GTV=22.86   ) 
    
e) CBCT 4 (GTV=22.15   )    f) CBCT 5 (GTV=18.74   ) 
Fig. 3.1 The planning CT and CBCT images for patient 5  
 
In total, 18 patients were available for the study. The local protocol for SABR treatments 
establishes three possible fractionations depending on tumour volume, range of tumour motion 
and proximity to organs at risk: 54 Gy in 3 fractions over 1 week, 55 Gy in 5 fractions over 2 
weeks or 60 Gy in 8 fractions over 2 weeks. Data obtained from patients following the 54 Gy 
in 3 fractions scheme was not used as it was decided that three data points are too few to 
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model, and thus these patients were excluded from the study. Table 3.1 provides an overview 
of the remaining 11 patients‘ data used in the study. Fig. 3.2 shows how GTV changes with 
time for all 11 patients; for clarity the patients were grouped according to the initial GTV 
(whether greater than 10    ). Table 3.2 shows GTV dynamics over time for all patients‘ data 
and it is presented in Appendix-i. 
 
Table 3.1 Patient and treatment characteristics 
Patient no. Age Gender No. of fractions Dose per fraction (Gy) 
1 81 Male 8 7.5 
2 68 Male 8 7.5 
3 89 Female 5 11 
4 83 Male 5 11 
5 84 Female 5 11 
6 83 Female 5 11 
7 83 Female 5 11 
8 75 Female 5 11 
9 56 Female 5 11 
10 83 Female 5 11 
11 79 Male 5 11 
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(a) 
 
(b) 
 
Fig. 3.2  GTV over time. (a) Patients‘ initial GTV is less than 10    ; (b) Patients‘ initial GTV 
is greater than 10    . 
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3.2. The tomotherapy data 
Twenty five patients, treated for NSCLC on the Hi-Art helical tomotherapy (Accuracy- Inc., 
Sunnyvale, CA) unit at the London Regional Cancer Program, Ontario, Canada, from 
December 2005 to March 2007, were used for this study. All patients received cisplatin and 
vinorelbine as neoadjuvant chemotherapy, finishing treatment 4-6 weeks before the start of 
radiotherapy. Chemotherapy is not expected to affect relative GTV changes from 
radiotherapy in patients because all patients were treated using the same regimen. The CT 
simulation and tomotherapy treatment planning (Hi-ART, version 2.2.2) occurred 
approximately 3 weeks before starting treatment, with delivery quality assurance performed 
to ensure proper dose distributions and absolute dose delivery. One initial mock treatment 
that included an MVCT (megavoltage computed tomography) study was performed for each 
patient, after which they began treatment with daily MVCT acquisitions for setup 
verification. A prescription dose of 60–64 Gy in 2 Gy/fraction was used for patients in this 
study, all of whom had locally advanced (Stages III-IV) disease. Elective nodal radiation was 
included for some patients, with doses of 50 or 60 Gy delivered to adjacent radiographically 
uninvolved nodal regions. The MVCT scans on the Hi-Art system were acquired with photon 
beam energy of 3.5 MV, field of view of 40 cm, fan beam width of 5 mm at the isocenter, and 
pitch factor of 2.4 for coarse (6-mm) slices. The reconstruction matrix was 512 × 512 in the 
axial plane, yielding a 0.78 × 0.78 × 6-mm
3 
voxel size.  For this research work, GTV volume 
changes were calculated retrospectively based on the serial MVCTs obtained daily during 
treatment. For calculation of GTV changes during the course of treatment, GTV was 
contoured after transferring the daily MVCT studies for each patient from the helical 
tomotherapy unit to a treatment planning system (either Pinnacle version 8.0d; Philips, 
Fitchburg, WI, or Oncentra Treatment Planning, version 1.3.1.13; Nucletron, Veenendaal, 
The Netherlands). The MVCT images were contoured with a window/level setting of 
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1600/300 for tumour bounded by parenchyma and 400/800 for tumour abutting the 
mediastinum. Involved nodes were excluded from the GTV; only primary tumour volume 
was measured for the purpose of calculating response in this report will be presented 
graphically which shows how GTV will change with respect to time during radiotherapy. Fig. 
3.3 shows how GTV changes with time for all patients; for simplicity the patients were 
grouped into two categories (whether initial GTV greater than 150    ). The uncertainties of 
the measured GTVs were established to be around 4%, see (Chvetsov et al., 2014) for 
detailed descriptions .Tables 3.3, 3.4, 3.5 and 3.6 respectively show GTV dynamics over time 
for all tomotherapy patients‘ data. In tables,   shows time while subscripts of GTV and   
express number of patient. These tables are presented in Appendix-ii. 
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(a) 
 
(b) 
 
Fig. 3.3 Summary of tomotherapy patients‘ data: (a) the initial GTV is less than 150 cm3; (b) 
the initial GTV is greater than 150 cm
3
. 
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CHAPTER 4 
MATHEMATICAL MODELLING OF TUMOUR VOLUME DYNAMICS 
 
In this chapter, mathematical modelling of tumour volume dynamics for SABR and 
tomotherapy patients‘ data are presented. Firstly exploration of simple to complex models, 
model calibration and selection are demonstrated. Secondly results and discussions for both 
sets of clinical data are conferred. At the end, the summary for mathematical modelling of 
tumour volume dynamics is discussed. 
 
4.1 The models  
A mathematical model may develop better understanding of the dynamics of cancerous tumour 
growth, prognosis for patients, effective treatment plans and response to therapy. An 
appropriate tumour growth model should satisfy the following criteria (Fernando and Miguel, 
2009): 
1- The model should have a physiological basis and should improve understanding of the 
dynamics of tumour growth with respect to time. 
2- The model should improve general understanding at macroscopic level of tumour 
growth and it should have breadth, in the sense that it should be applicable to different 
patients with the same type of tumour. 
3- The model adequacy should be balanced in-term of complexity and goodness of fit to 
patient data.  
The main objective of this study is to develop mathematical models in a pragmatic way. That 
is, the models should include sufficient details of radiobiology in order to be able to describe 
the clinical measurements. On the other hand, including very detailed microscopic phenomena 
may not be desired for clinical use because these phenomena are not routinely measured in 
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practice. Such consideration has not been properly explored in modelling tumour volume 
dynamics. This is in addition to the fact that SABR has not been modelled. As a result, we aim 
to keep a balance between model accuracy and complexity, assessed by available data.  
The above consideration has precluded the use of spatially distributed models, such as 
those based on two/three-dimensional partial differential equations (Rockne et al., 2010), 
because the measured tumour volume on CT images does not contain such information. 
Therefore, this study focuses on ordinary differential equation based models, and explores a 
range of modelling options in terms of how well they describe the clinical data. These models 
have been well reported in the literature for modelling generic tumour growth and response to 
radiotherapy (Byrne, 2003; Bresch et al., 2010; Ribba et al., 2006; McAneney et al., 2007; 
Ward & King, 1997), though they have not been applied to NSCLC patients receiving SABR. 
Hence in the light of trade-off between model accuracy and complexity, both clinical data sets 
(SABR and tomotherapy patients‘ data) will be modelled by exploring a range of mathematical 
modelling options. 
 
4.1.1 One-population tumour growth models 
The first modelling option is to assume that the GTV consists of homogeneous tumour cells, 
and thus it can be described by a single variable, the volume (N). This is certainly an idealised 
assumption, yet a clinical useful one, since tumour volume has been demonstrated to be an 
important indicator of treatment prognosis (Bentzen & Thames, 1996; Dubbena et al., 1998; 
Willner et al., 2002). In addition, although CT images may imply tumour heterogeneity in 
terms of density on the Hounsfield scale, it is not clear how this information can be included in 
modelling and will need to be investigated in the future. A potential route is through image 
texture analysis; see e.g. (Alobaidli et al., 2014). The first model also employs a simple 
exponential kinetics for tumour growth, resulting in the following equation: 
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where t is time, and k>0 is the proliferation rate. To fully simulate GTV over time, this model 
also needs the initial volume, which can be taken from the first CT measurement. In this 
model, there is no constraint on cell growth: all nutrients and other vital growth factors are 
assumed to be available in abundance. This is a reasonable assumption for stage 1 NSCLC 
(SABR patients‘ data) and late stage NSCLC (tomotherapy patients‘ data). Clearly, without 
treatment, the model predicts that the tumour will grow exponentially without limit. 
The effect of radiotherapy is modelled by the conventional linear-quadratic (LQ) equation 
(McAneney et al., 2007; Sach et al., 1997; Fowler, 2006), which describes the proportion of 
tumour cell surviving irradiation: 
                    (4.2) 
where   represents survival fraction,   is the dose per fraction, while   and    are the linear 
and quadratic coefficients for cell killing, respectively. Hence, when tumour is irradiated at 
time    then after infinitesimal time      the tumour volume will be: 
                    (4.3) 
As there are two different sets of clinical data (SABR and tomotherapy patients‘ data) studied 
in this research work. The LQ model was originally devised for small radiation dose, e.g. the 
typical 2 Gy per fraction. It means that LQ model is applicable for tomotherapy patients‘ data. 
But in case of SABR patients‘ data, high dose (7.5 or 11 Gy per fraction) is used, arguably 
alternative models should be adopted. Park et al. (2008) proposed a ―universal‖ survival model, 
combining the LQ equation for low dose and the multi-target model for high dose. Below a 
certain cut-off dose (i.e., dose     , the LQ equation should be used. 
Although the multi-target model appears to be theoretically appealing, it has been under 
debate in relation to the LQ equation in high dose radiation. There exists long standing 
 
 
52 
 
experimental results, suggesting that the multi-target model over-estimates cell survival even at 
high dose (Barendsen et al., 1960), and thus the LQ equation may still be appropriate (Brenner, 
2008; Fowler, 2008). Therefore, the LQ equation is adopted in SABR and tomotherapy 
patients‘ data.  
It should be noted that, from the clinical data (SABR and tomotherapy patients‘ data) 
provided, it is not possible to estimate both   and   in the LQ equation for each patient. This is 
because the models intend to describe the GTV dynamics for individual patients, and each 
patient‘s dose per fraction is fixed. Hence, effectively only survival fraction   can be estimated 
for each patient. Given particular   and  , there exists infinite combinations of   and   that 
satisfy equation (4.2). However, we do wish to assess the impact of dose across different 
patients who may have different dose per fraction, and thus estimating   only is not adequate. 
As a result, we chose to fix the     ratio to 10 Gy, following the literature reports for lung 
cancer (O'Rourke et al., 2009; Guckenberger et al., 2013), and to estimate   only. 
Equations (4.1), (4.2) and (4.3) are referred to as ‗one population exponential growth 
model‘ (POP1-EXP). More complex cell growth mechanisms can be introduced to provide 
more realistic representation of the tumour behaviour. Specifically, the well-known logistic 
growth model is also considered: 
  
  
   (  
 
 
)     (4.4) 
where   represents the rate of proliferation and     is the ―carrying capacity‖ of the cell 
population. Under such a logistic model, the initial stage of cell growth is approximately 
exponential until the volume becomes comparable with the carrying capacity. Then, the growth 
slows down until reaching the maximum possible volume ( ). By constraining the tumour 
volume to a maximal size, due to, for example limited space, nutrients and other growth 
factors, the logistic model is more realistic than the exponential growth. However, it also 
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carries one extra parameter,   which needs to be estimated. Whether the additional complexity 
is justified in relation to improved model accuracy will be explored in the subsequent sections. 
Coupling the logistic growth in equation (4.4) with the LQ equation in equations (4.2) and 
(4.3), this model is referred to as ‗one population logistic growth tumour model‘ (POP1-LOG) 
hereafter. 
 
4.1.2. Two-population tumour growth model 
Among various limitations, one main difficulty of modelling tumour as a homogeneous volume 
is that the tumour volume would shrink instantaneously after receiving radiation. In reality, the 
cell death and ultimate clearance (disintegration) from tumour involve complex pathways and 
may take considerable time. Such a process may be modelled by introducing a simple time 
delay term in equation (4.3), or more commonly by using two populations of tumour cells: 
living and dead (Wang & Feng, 2013; Chvetsov et al., 2009). In this approach, living tumour 
cells (volume:   ) still proliferate according to either the exponential growth:  
   
  
        (4.5) 
or the logistic growth: 
   
  
    (  
  
 
)    (4.6) 
Upon receiving radiation, a fraction of the living cells can survive irradiation according to the 
LQ equation in equation (4.2), and the rest become dead.  
                     (4.7) 
                    [         (4.8) 
where    is the volume of dead cells, which will be cleared from the tumour exponentially: 
   
  
          (4.9) 
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where     is the clearance rate. As a result, the tumour volume, as measured in CT images, 
is the sum of that of living and dead cells: 
           (4.10) 
It should be noted that this two-population approach is introduced not because CT imaging can 
differentiate between living and dead cells. Rather, it should be regarded as a modelling 
method which may be pragmatically necessary to describe the delay in volume shrinkage after 
irradiation, and at the same time it contains theoretically founded mechanisms of cell death and 
clearance. The resulting models are referred to as ―POP2-EXP‖ with exponential living cell 
growth (equations (4.2), (4.5), and (4.7) to (4.10)), and ―POP2-LOG‖ with logistic living cell 
growth (equations (4.2), and (4.6) to (4.10)), respectively. 
In summary, the four models considered in this study are listed in Table 4.1. These models 
have different degrees of complexity and number of parameters. It might be tempting to 
introduce more detailed radiobiological phenomena into the modelling equations, resulting in 
even more complex models. However, when judged by the intended use, especially use in 
clinical practice, additional complexity may not bring significant benefit. For example, 
although the logistic growth is closer to the underlying biological mechanisms than the 
exponential kinetics, it may not give significantly better results when the tumour is being 
treated. In addition, the logistic growth model introduces one extra parameter, and it may not 
be well calibrated to limited clinical data. Therefore, given the variety of models available, an 
important task of this study is to apply statistical model selection criterion for selecting a 
mathematical model that is not so simplistic as to be unable to describe the clinical data, and 
also not unnecessarily complex. This will be discussed in Sections 4.2, 4.3 and 4.4 
respectively. 
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Table 4.1 Summary of radiobiological models 
Growth models Model abbreviation Parameters 
       
One population  exponential POP1-EXP     
One population logistic POP1-LOG       
Two population exponential  POP2-EXP       
Two population logistic  POP2-LOG         
 
 
4.2 Model calibration and selection 
For the measure of modelling compatibility in case of individual patient, the models are 
calibrated for each  patient of both data sets (SABR and tomotherapy patients‘ data) by 
estimating the model parameters (listed in Table 4.1 for each of the four models) using 
maximum likelihood method. More specifically, the following optimisation problem is solved 
by using interior point method (MATLAB Optimisation Toolbox, Fmincon), to identify the 
model parameters: 
    ∑[      ̂   ]
 
 
   
   (4.11) 
Where SSE stands for sum of squared errors,       is the measured GTV right before the  -th 
fraction and   is the total number of fractions for a particular patient, and  ̂    is 
correspondingly modelled GTV. The optimisation is also subject to constraints on the lower 
and upper bounds of the model parameters, in order to avoid obtaining physically impossible 
parameter values. Where possible, the parameter bounds are based on typical values reported in 
the literature but also significantly extended from these typical values. Such extension is 
needed to account for the different treatment methods and inter-patient variability, and to allow 
 
 
56 
 
sufficient freedom for the model to fit to individual patients. In particular, the parameter 
bounds are explained as: 
 The rate of proliferation for NSCLC,          , was reported to be in the range of 
[0.001, 0.086] (Sharouni et al., 2003), which was used as the bounds in this research.  
 The carrying capacity,        , varies from patient to patient. Since the lower and 
upper bound are set differently from patient to patient. As a result, lower bound set on 
the basis of maximum GTV of that specific patient, while upper bound is set much 
higher than maximum GTV value of that particular patient.  
 The survival fraction of NSCLC cell lines under 2 Gy was reported to be between 0.164 
and 0.922 (Sharouni et al., 2003), which is equivalent to a range of [0.0338, 0.7533] for 
the linear radiobiological parameter,         , by fixing     to 10 Gy.  
 The clearance rate for dead tumour cells,          , was reported to be 0.0246, 0.0096 
and 0.0383 for different tumours (Chvetsov et al., 2008; 2009). Literature data are 
sparse for this parameter. In order to allow sufficient freedom for parameter estimation, 
the bounds were expanded to set as [0.0045, 0.0540]. 
The root mean squared error (RMSE, i.e., √     ) and the percentage RMSE, will be reported 
to assess model goodness-of-fit. Modelling and optimisation are all implemented in 
MathWorks‘ Matlab computation environment (using the interior point method). The classic 
Pearson‘s correlation analysis will also be carried out for the estimated model parameters 
across different patients. The purpose is to examine the dependency of these parameters. 
According to theories in systems engineering, if the model parameters are highly correlated and 
thus dependent on each other, they are not fully identifiable from available data (Ben-Zvi, 
2008; Bearup et al., 2013, Yue et al., 2006). Consequently, care must be taken when 
interpreting the obtained parameter values. This issue will be further addressed with the results 
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in Sections 4.3 and 4.4. Theoretical studies of model identifiability can be found in the 
literature of systems engineering (Ben-Zvi, 2008; Bearup et al., 2013, Yue et al., 2006). 
Faced with four modelling options, a systematic approach to selecting an appropriate 
model is needed. If a model is complex with a large number of free parameters, it would fit the 
data better than a simpler model. Although complex models are indeed useful to help elucidate 
the detailed mechanisms involved, when calibrated to actual measurements they tend to ―over-
fit‖ the data and do not generalise well to predict unseen measurements. Therefore, a range of 
statistical methods have been proposed to keep a trade-off between goodness of fit and model 
complexity (in terms of the number of free parameters). Three widely used criteria (Burnham 
& Anderson, 2002; Honjo, 1994; Wang & Liu, 2006; Harada et al., 2010; Lancelot et al., 2002) 
are the Akaike information criterion (AIC): 
                                                                                   (4.12) 
the corrected Akaike information criterion (AICc) is presented as: 
                (
 
     
)                                               (4.13)                
and the Bayesian information criterion (BIC) becomes as:  
                                                                                     (4.14) 
where   is the number of free parameters,   is the number of data points for a particular patient 
(which equals the number of fractions since CT scan was done prior to each fraction), and   is 
the maximum likelihood after model calibration. The model with the minimum AIC, AICc or 
BIC should be chosen. 
The AIC penalises the number of parameters less strongly than the BIC does, when the 
number of data points is more than seven (or      ). It was shown that AIC has certain 
theoretical advantages over BIC, and empirically AIC also tends to select more appropriate 
model in simulation studies (Burnham & Anderson, 2002; Yang, 2005). The provided clinical 
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data for this study has small sample size, whereas AICc should be used for small data size. As 
a result, AIC and AICc are used in this study. Further, a non-parametric statistical technique 
(the paired Wilcoxon rank sum test) is used to determine statistically significant of RMSEs and 
AICs values that are obtained by different models (Gibbons & Chakraborti, 2011).  
Further, it should be noted that it is possible to calibrate the model to the entire population 
of the patients. However, the population approach was not explored in SABR and tomotherapy 
patients‘ data because, firstly, the intended use of the model is to provide information about 
how individual patients respond to SABR and tomotherapy in terms of GTV dynamics. In 
addition, since only a small number of patients are available, the obtained population 
parameters may not be generalisable to a larger patient cohort. 
 
4.3 Results 
This section presents the results of models calibrated for two data sets (SABR and tomotherapy 
patients‘ data), and the selection of the appropriate model in terms of complexity and accuracy.   
 
4.3.1 Results for SABR patients’ data 
Firstly results for SABR patients‘ data are presented. Table 4.2 summarises the calibration 
results of the four models. It appears that, in general, when the model becomes more complex 
(from POP1-EXP to POP1-LOG, and POP2-EXP to POP2-LOG), the modelling error is also 
reduced. Including carrying capacity (thus exponential growth becoming logistic growth) only 
provides marginally better accuracy (RMSE reduced from 5.77 to 4.84% for one population 
model, and from 0.96 to 0.90% for two population). In addition, the estimated model 
parameters are significantly different across patients; for example for the simplest model, 
POP1-EXP, the median estimate of proliferation rate (k) is 0.0340       but with a fairly wide 
range of [0.001, 0.086]. Furthermore, the estimated model parameters also change significantly 
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from one model to another For instance, the linear radiation effect ( ) is much smaller in the 
one-population models (median: 0.0338 for POP1-EXP and 0.0338 for POP1-LOG) than it is 
in the two-population models (median: 0.50 for POP2-EXP and 0.50 for POP2-LOG). These 
observations will be discussed in section 4. 
The correlations between estimated model parameters are presented in Table 4.3. Although 
the correlation coefficients are statistically insignificant (all   values greater than 0.05), they do 
indicate that the model parameters are somewhat dependent on each other when calibrated to 
patient data.   
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Table 4.2 Summary of the model calibration results for the SABR data 
 
                                      RMSE (%) AIC AICc 
Bound [0.001, 0.086] [0.0338, 0.7533] [-
*
, 100] [0.0045,0.0540]    
POP1-EXP        
    median 0.0340 0.0338 - - 5.77 -5.98 -6 
    range [0.0010, 0.086] [0.0338, 0.1455] - - [0.52,10.12] [-35.17,4.45] [-36, 5] 
POP1-LOG        
    median 0.0371 0.0338 32 - 4.84 -5.50 -7 
    range [0.0010, 0.086] [0.0338, 0.1065] [10, 70] - [0.52,10.12] [-33.70,6.40] [-34, 7] 
POP2-EXP        
    median 0.001 0.50 - 0.03 0.96 -10.7 -10 
    range [0.001, 0.086] [0.25, 0.753] - [0.02, 0.05] [0.25,4.99] [-37,-2.50] [-37, 3] 
POP2-LOG        
    median 0.001 0.50 40 0.05 0.90 -7.7 -7 
    range [0.001, 0.086] [0.04, 0.753] [15, 83] [0.02, 0.05] [0.25,4.99] [-34,-0.50] [-35, 5.5] 
 
*
The lower bound of carrying capacity depended on individual patients and was set to the maximum GTV of each particular patient.
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Table 4.3 Correlation coefficients between estimated parameters (SABR data), where all   
values are greater than 0.05, indicating that the correlations are statistically insignificant. 
       
POP1-EXP    
      0.46 - - 
    
POP1-LOG    
      0.32 0.01 - 
     - 0.43 - 
    
POP2-EXP    
      0.33 - 0.41 
     - - -0.10 
    
POP2-LOG    
      0.30 -0.36 0.43 
     - -0.10 -0.30 
     - - -0.19 
    
 
Figures 4.1-4.3 illustrate the GTV dynamics for three representative patients with the lowest 
(Fig. 4.1, patient 10), median (Fig. 4.2, patient 11) and highest RMSEs (Fig. 4.3, patient 9), 
respectively as obtained from the POP2-EXP model. Overall, the POP2-EXP model fits 
reasonably well to the patients‘ data through the use of two populations of tumour cells. Even 
for patient 9 with the highest RMSE, the POP2-EXP model is still able to follow the main 
trend. In addition, the model suggests that at the end of treatment, tumours have significant 
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portions of both living and dead cells; see figures 4.1(a), 4.2(a) and 4.3(a). This appears to be 
reasonable, since for the short treatment time (maximum 9 days) of SABR, the dead cells may 
have not been fully cleared. Fig. 4.4 presents the overall satisfactory modelling results of 
POP2-EXP, by plotting the fitted GTV against measured values for all 11 patients.  
(a) 
 
(b) 
 
Fig. 4.1 GTV dynamics for patient 10 (RMSE=0.25%, the lowest obtained from POP2-EXP): 
(a) detailed results of POP2-EXP; (b) comparison between POP2-EXP and other models. 
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(a) 
 
(b) 
 
Fig. 4.2 GTV dynamics for patient 11 (RMSE=0.96%, the median obtained from POP2-EXP: 
(a) detailed results of POP2-EXP; (b) comparison between POP2-EXP and other models. 
 
 
 
 
 
64 
 
(a) 
  
(b) 
 
Fig. 4.3 GTV dynamics for patient 9 (RMSE=4.55%, the highest obtained from POP2-EXP: (a) 
detailed results of POP2-EXP; (b) comparison between POP2-EXP and other models. 
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Fig. 4.4 Overall fitting of GTV dynamics for 11 patient‘s data 
Finally, Fig. 4.5 illustrates the box plots that summarise the performance of the four models in 
terms of RMSE, AIC and AICc. By looking at RMSE alone, the model fitting results tend to be 
better when the model becomes more complex, and this observation holds not just for the 
median RMSE (also c.f. Table 4.2) but also for the RMSE distribution as shown in the box 
plots. However, this is not the case if the models are judged by AIC and AICc, a criterion 
balancing between fitting performance and model complexity. The median AIC and AICc  
decrease from the simplest model, POP1-EXP (AIC=-5.98, AICc=-6) to complex model, 
POP1-LOG (AIC=-5.50, AICc=-7), and POP2-EXP (AIC=-10.70, AICc=-10).  
However, when more complex models POP2-LOG, the value of AIC and AICc increase to 
-7.70 and -7, suggesting that the extra complexity is not well supported by the data. The same 
trend can be observed from the distribution of AIC and AICc values, not just the median. As 
AIC and AICc have similar results for SABR patients‘ data in term of model selection, hence 
model will be selected on the basis of AIC for this specific clinical data. The paired Wilcoxon 
rank sum test was further applied to test the statistical significance of the differences in RMSEs 
and AICs. For RMSE, the two-population models (POP2-EXP and POP2-LOG) have 
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significantly lower RMSEs than the one-population models (p<0.01 in all cases), but POP2-
EXP and POP2-LOG have similar median RMSE (p=0.50). In terms of AIC, POP2-EXP is 
significantly better than POP2-LOG, and POP1-LOG (p<0.05 in all cases), but the significance 
is less so when compared with POP1-EXP (p=0.07). 
(a) 
 
(b) 
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(c) 
 
Fig. 4.5 Box plots to compare the four models for fitting all 11 patients: (a) RMSE (%);  
(b) AIC  (c) AICc 
 
4.3.2 Results for tomotherapy patients’ data 
Secondly results of tomotherapy patients‘ data are presented. Results are analysed in terms of 
appropriate selection of model by considering the model complexity and accuracy factors, the 
overall relation between model fitting and measured data, model calibration against patient‘s 
data, estimated parameters range during calibration of model. 
Table 4.4 exemplifies the calibration results of six mathematical models. Henceforth it 
provides an overview and distribution of estimated parameters, their bound and additionally 
tells about the range of RMSE during model fitting of patient‘s data. By looking at table 4.4, it 
indicates that % RMSE varies from simple to complex models. Further, it is observed that the 
estimated model parameters are significantly different across patients and from model to 
model. For instance, the linear radiation effect ( ) is much smaller in the one-population model 
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than it is in the two-population model. These observations will be discussed in next section 
(section 4.4).  
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 Table 4.4 Summary of the model calibration results for the tomotherapy data 
                                      RMSE (%) AIC AICc 
Bound [0.001, 0.086] [0.0338, 0.7533] [-
*
, 1500] [0.0045,0.0540]    
POP1-EXP        
    median 0.0371 0.042 - - 8.85 108 109 
    range [0.012, 0.049] [0.0338, 0.15] - - [2.52,18.61 ] [-38,243] [-38, 244] 
POP1-LOG        
    median 0.0371 0.040 899 - 8.39 109 110 
    range [0.001, 0.086] [0.0338, 0.14] [18, 1200] - [2.51,18.61] [-36,274] [-35, 275] 
POP2-EXP        
    median 0.0016 0.4824 - 0.0155 5.43 79 81 
    range [0.001, 0.086] [0.0338, 0.753] - [0.0045, 0.041] [2.42,14.35] [-51,245] [-50, 246] 
POP2-LOG        
    median 0.0016 0.4079 100 0.0155 5.43 81 84 
    range [0.001, 0.086] [0.0338, 0.753] [50, 1200] [0.0045, 0.041] [2.42,14.35] [-49,247] [-48, 248] 
*
 The lower bound of carrying capacity depended on individual patients.  
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The correlations between estimated model parameters are presented in Table 4.5. Whereas 
the correlation coefficients are statistically insignificant they do designate how model 
parameters are dependent on each other while calibrated to tomotherapy patients‘ data.  
       
       
Table 4.5 Correlation coefficients between estimated parameters (tomotherapy data), where 
all   values are greater than 0.05, indicating that the correlations are statistically insignificant. 
       
POP1-EXP    
  0.73 - - 
    
POP1-LOG    
  0.15 -0.20 - 
  - 0.30 - 
    
POP2-EXP    
  0.83 - -0.23 
  - - -0.29 
    
POP2-LOG    
  0.81 0.02 -0.10 
  - 0.09 -0.38 
  - - -0.41 
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Figure 4.6 illustrates overall model fitting results against tumour volume of 25 patient‘s 
data. From the figure, it is cleared that how close model is fitted for tumour volume data. For 
instance, it shows a linear relation between model fitting results and GTV and also provides 
an overview of model fitting performance.  
Figures 4.7-4.9 demonstrate the profile of GTV dynamics for three patients having least, 
median and highest RMSE for patient 9, patient 6 and patient 19 respectively as obtained 
from the POP2-EXP model.  Largely, the POP2-EXP model provides reasonable fitting 
results comparatively to remaining modelling options. Even for patient 19 with the highest 
RMSE, the POP2-EXP model is still appropriate amongst others to provide better model 
fitting results.  Figures 4.7(a), 4.8(a) and 4.9(a) present the similar trend of living and dead 
cells in POP2-EXP as seen in SABR patients‘ data.  
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 (a) 
 
 
(b) 
 
Fig. 4.6  GTV dynamics for patient 9 (RMSE=2.42%, the lowest obtained from POP2-EXP): 
(a) detailed results of POP2-EXP; (b) comparison between POP2-EXP and other models. 
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(a) 
 
(b) 
 
Fig. 4.7  GTV dynamics for patient 6 (RMSE=5.43%, the median obtained from POP2-EXP: 
(a) detailed results of POP2-EXP; (b) comparison between POP2-EXP and other models 
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(a) 
  
 
(b) 
 
Fig. 4.8 GTV dynamics for patient 19 (RMSE=14.35%, the highest obtained from POP2-
EXP): (a) detailed results of POP2-EXP; (b) comparison between POP2-EXP and other 
models. 
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Fig. 4.9 Overall fitting of GTV dynamics for 25 patient‘s data 
However, figure 4.10 demonstrates the box plots that quantifying the performance of the six 
models in terms of % RMSE, AIC and AICc. As in the light of %RMSE distribution of 
available mathematical models, the complex models has better fitting results comparatively to 
simple ones. For instance, one population tumour growth (POP1-EXP and POP1-LOG) 
models have slightly higher median RMSE than two population tumour growth models 
(POP2-EXP and POP2-LOG). It means that the median RMSE of complex model decreases 
by the addition of extra parameter comparatively to simple one. As in the light of RMSE 
results, more complex models give better model fitting results.  
Though to avoid from the over-fitting, under-fitting and model complexity, models are 
not just judged on the base of RMSE results, while a model selection criterions (AIC and 
AICc) that are a balancing trade-off between fitting performance and model complexity are 
used to select appropriate model. As, the median AIC and AICc (refer to Fig. 4.10(b) and Fig. 
4.10(c)) vary from the simplest model, POP1-EXP (AIC=108, AICc=109), to complex POP1-
LOG (AIC=109, AICc=110) and POP2-EXP (AIC=79, AICc=81) models. Conversely, when 
more complex model, POP2-LOG is practised, the AIC and AICc upsurge to 81 and 84 
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respectively. It means that extra complex model is not good enough for the available data. In 
tomotherapy data, the AIC and AICc have pretty much same effect in model selection, hence 
model is chosen on the basis of AIC results. Conversely, further it is supported by the paired 
Wilcoxon rank sum test to further investigate the statistical significance in terms of 
differences in RMSEs and AICs. In case of RMSE, the two-population models have 
significantly lower RMSEs than the one-population models (p<0.01), however in terms of 
AIC   POP2-EXP is significantly better than other modelling approaches (p<0.06 in all 
cases), but the significance is less so when compared with POP1-EXP (p=0.08) 
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(a) 
 
(b) 
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(c) 
 
Fig. 4.10  Box plots to compare the four models for fitting all 25 patients: (a) RMSE (%); 
(b) AIC (c) AICc 
 
4.4 Discussions 
The first important observation during the study of SABR and tomotherapy patients‘ data is 
the significant variability of the estimated model parameters across different patients. This 
large inter-patient variability suggests that, if the model is intended to describe GTV 
dynamics for individual patients, then a population modelling approach may not be desired. 
Similar inter-patient variability, and thus the choice of individual modelling, can be seen in 
related tumour volume studies (Chvetsov et al., 2009; Filipovic et al., 2014; Seibert et al., 
2007). 
Secondly, it is important to note that although the model parameters have underlying 
physical meaning, their calibrated values (for both sets of clinical data) also depend on the 
choice of model. For example, the linear radiation effect ( ) is small for one-population 
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models, which is consistent with the modest reduction of tumour volume during SABR 
(SABR is currently used for early-stage NSCLC patients with small initial volume). Whereas 
in case of tomotherapy patients‘ data (late stage NSCLC), the linear radiation effect is 
slightly higher than SABR patients‘ data for one population models. This is because 
tomotherapy patients‘ data have higher volume reduction (due to large in size) in comparison 
with radiotherapy of SABR patients‘ data. But when the two-population models for SABR 
(POP2-EXP and POP2-LOG) are considered, the estimated   is larger and also closer to 
reported values in the literature (Chvetsov et al., 2009; Rockne et al., 2010; South et al., 
2008). However, when two population models (POP2-EXP and POP2-LOG) are used for 
tomotherapy patients‘ data, the estimated   is high comparatively to one population models 
but it is not that much big as seen in SABR patients‘ data.  As a result, it is discerned that due 
to different in sizes of early and late stage NSCLC, the tomotherpy patients‘ data have less 
estimated   value than SABR. Becuase, the clearance mechanism is included in two-
population models; therefore the higher impact of irradiation (large  ) can be off-set by a 
slow clearance (small c) of dead tumour cells, and thus overall the tumour volume still 
reduces modestly and slowly. In other words, the estimated   is correlated with c. Correlation 
also exists for other pairs of parameters (see Table 4.3 for SABR and Table 4.5 for 
tomotherapy patient‘s data); for example a positive correlation between   and   means that 
higher proliferation could be off-set by higher impact of radiation, so as to fit the patient data.  
The correlation phenomenon analysed above suggests that it is not possible to fully 
identify all model parameters purely from the both sets of patient data. Given the extensive 
literature on   values, the two-population models may be more desired because they push the 
estimated   closer to what has been reported. Nevertheless, this observation discourages us to 
view the obtained parameters as ―true‖ physical quantities, since they are not entirely 
identifiable from available data. For more discussions on model identifiability issues, the 
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readers are referred to excellent studies from the community of systems engineering (Ben-
Zvi, 2008; Bearup et al., 2013, Yue et al., 2006). Instead, the models (and obtained 
parameters) should be regarded as computational tools, developed based on accepted cell 
growth and radiobiological mechanisms, for describing the tumour volume dynamics and 
providing potentially useful information to clinicians. 
Thirdly, apparent tumour growth can be observed during the treatment for some patients 
in early and late stage NSCLC, for example Patient 9 (in SABR patients‘ data)  shown in Fig. 
4.3 and patient 19 (in tomotherapy patients‘ data) presented in Fig. 4.8. There are a number of 
potential explanations for this phenomenon: 
 Actual tumour growth (proliferation); 
 Inflammatory response to treatment (tissue swelling);  
 Uncertainties in contouring (due to image artefact, or intermediate density tissues 
close to the tumour);  
 Radiation-induced changes to normal lung tissues surrounding tumour (increased 
density);  
 Changes in breathing pattern or patient motion, e.g. increase in breathing amplitude.  
It is likely that a number of these factors may have combined to produce this apparent 
growth, but in the model only the first is explicitly represented. This again suggests that the 
calibrated parameter parameters may not be interpreted as the true physical values. 
Finally, both the RMSEs  ( refer to Tables 4.2 and 4.4), and the graphic results (refer to 
figures 4.1-4.3, and from 4.7-4.9) for SABR and tomotherapy patients‘ data show that the use 
of a logistic growth model has marginal impact on model accuracy. In some cases (during 
study of both sets of data), the fitted GTVs are almost the same for exponential and logistic 
growth models (i.e. POP1-EXP vs. POP1-LOG, and POP2-EXP vs. POP2-LOG). Intuitively, 
the POP2-EXP model may give a reasonable balance between model complexity and 
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accuracy. In contrast, it appears that introducing an extra cell population (dead cells) is 
needed to allow sufficient time for the tumour to shrink in response to irradiation. These 
intuitions are further justified by examining the AIC values (for both sets of data) which 
balance between fitting performance and model complexity, and supported by the use of a 
rigorous statistical hypothesis test (the paired Wilcoxon rank sum test). Consequently, the 
POP2-EXP model appears to be a reasonable choice for the given sets of data (SABR and 
tomotherapy patients‘ data). 
 
4.5 Summary 
This chapter presents a mathematical modelling approach to describing tumour volume 
dynamics in response to SABR and tomotherapy for early and late stage NSCLC. A variety 
of options for model formulation (POP1-EXP, POP1-LOG, POP2-EXP, POP2-LOG,) are 
analysed, and the models are calibrated by using maximum likelihood estimation approach to 
SABR and tomotherapy patients‘ data.  
The results demonstrate that relatively simple models are adequate in modelling tumour 
volume dynamics. In addition, a rigorous model selection method is applied to help decide 
the most appropriate model, given the available data. The results suggest that the POP2-EXP 
model (two populations of tumour cells, living and dead, with exponential tumour growth) 
appears to be a reasonable choice for modelling GTV dynamics of NSCLC patients treated by 
SABR and tomotherapy.  
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CHAPTER 5 
BAYESIAN MODEL ADAPTATION 
 
This chapter presents the application of the Bayesian method for adaptive prediction. The 
maximum a posterior (MAP) is presented for model adaptation, and the calculation of the 
prior and likelihood function is discussed. The method is applied to the tomotherapy data set 
with promising results achieved. 
 
5.1 The Bayesian method 
The main idea of adaptive prediction is to sequentially improve the prediction of a patient‘s 
response to therapy by using data collected during the treatment. When a new patient enters 
the treatment, the response will be predicted based on a population-averaged model and 
initial GTV. Subsequently during the treatment, the population model is updated using the 
GTV measurement of this specific patient, so that the model becomes more and more 
personalised and the prediction becomes more accurate. Model adaptation will be 
implemented through a Bayesian parameter estimation method (Gelman et al., 1995), which 
facilitates a smooth transition from the population-averaged to a patient-specific model. 
The Bayesian approach synthesises two sources of information about the model 
parameters. The first is the prior distribution corresponding to the information about 
population patients in this study (Lee 2012; Stevens 2009; Congdon 2006; Berry 2006). The 
second is the likelihood function that represents the data of a specific patient. Let   be the set 
of model parameters and   denote the data of the patient, Bayes theorem results in the 
following posterior distribution of the parameters    |  : 
   |           |                                                           
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where      is the prior and    |   the likelihood. In equation (5.1), the likelihood function 
is the same as that used for model calibration (chapter 4). The prior distribution is derived 
from the parameters estimated in the model calibration stage (Section 4.2). Model adaptation 
is achieved by searching for the value of parameters that maximise the posterior probability 
density function given in equation (5.1). Subsequently, the updated parameter value is used 
for predicting the tumour volume change towards the end of treatment.  
 
5.2 The prior  
A random variable can be thought of as a variable that takes on a set of values with specified 
probability. In frequents statistics, parameters are not random, but fixed, quantities. (David et 
al. 2004; Lee 2012; Stevens 2009; Congdon 2006; Berry 2006). In contrast, in Bayesian 
statistics anything about which we are uncertain, including the true value of parameters, can 
be thought of as being a random variable to which we can assign a probability distribution, 
known as prior information. A Bayesian analysis should always incorporate genuine prior 
information, which will help to strengthen inferences about the true value of the parameter 
and ensure that any relevant information about it is not wasted (Vaseghi 2000; Lee 2012; 
Stevens 2009; Congdon 2006; Berry 2006). As the maximum posteriori estimation (MAP) is 
based on the combined sources of information (prior and likelihood) (Gauvain et al. 1994), 
prior information has significant importance (Kenneth 2007).  
In this research, GTV data for locally advanced NSCLC of 25 patients under 
tomotherapy treatment are used, hence prior for each individual patient data is calculated 
from the estimated parameters of all but excluding that patient. This ensures that the prior 
distribution does not contain any specific information from the new patient to be predicted.  
For each of the model parameters, a log-normal distribution is established from the 24 values 
of the population patients. Log-normal distribution is used because all model parameters are 
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positive (chapter 4). The model parameters are assumed independent a priori, thus the 
probability density function (pdf) for one parameter     will be, 
     = 
 
   √  
   * 
           
 
    
+                                         (5.2)     
where    stands for standard deviation of the parameter     and     is the mean. The overall 
prior distribution is a product of the log-normal distributions of the n parameters, hence  
      ∏     
 
   
                                                                            
Specific to this work, the parameter     consists of  ,   and    The above method of 
obtaining population parameter distribution is a two-stage approach, since it estimates the 
parameter values for individual patients first, prior to combining them into a distribution. The 
two-stage approach is used in this study, because we need to assess the model goodness-of-fit 
for individual patient; it was shown to produce similar results when compared with the more 
rigorous, non-linear mixed-effect approach for obtaining population parameter distribution 
directly (Hahn et al., 2011). 
 
5.3 Maximum a posteriori estimation 
The maximum a posteriori (MAP) estimate  ̂   is obtained as the parameter that maximizes 
the posterior probability density function (pdf). Thus from equation (5.1) and equation (5.3), 
 ̂    will be (Bishop 2009; Kenneth 2007; David et al. 2004; Lee 2012; Vaseghi 2000); 
                                                   ̂                      |                                    (5.4)                                    
here      is the probability of prior information that represented by equation (5.3) and 
   |   is likelihood function. 
The MAP estimation is proportional to the product of probability density function of 
prior and likelihood (Bishop 2009; Kenneth 2007; David et al. 2004; Lee 2012).The  
probability density function (pdf) for likelihood will be; 
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In equation (5.5) (Bishop 2009, Kenneth 2007),     stands for standard deviation of likelihood 
function,    stands for gross tumour volume for fraction   and  ̂  is the model tumour volume 
for fraction   and    presents total number of fractions.   
The objective of MAP estimation is to find the most probable values for a set of 
parameters by maximizing the posterior distribution, analogous to maximum likelihood 
estimation. Hence, by implementing the equation (5.4), model is adapted from the first 
fraction of radiotherapy until the last one through re-estimating model parameters. The MAP 
method is used for predicted change of tumour volume could be used to aid clinical decisions 
for personalised treatment. The predictive performance of MAP Bayesian estimation was 
evaluated by calculating the percentage RMSE (%). 
In summary, the MAP method runs as follows: 
1. At the beginning of treatment, use the prior parameter values and give dose schedule 
to predict the GTV dynamics. 
2. At each fraction when a new GTV measurement is available, solve the constrained 
(range of parameters is presented in section 4.2) optimisation problem in equation 
(5.4) by using the interior point method (MATLAB Optimisation Toolbox, Fmincon). 
3. Update the prediction by using the newly estimated model parameters in step 2. 
4. Continue with step 2 until the end of treatment. 
The above four steps are applied to each patient. Debatably, the parameters can be updated by 
maximising the likelihood function of patient-specific data only, which is a method widely 
used in the biomedical community (Chen et al., 2012; Noble et al., 2010). However, the 
Bayesian approach provides a natural combination of information from population and 
individual. This is especially useful at the initial stage of the treatment, when the patient-
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specific data is scarce and maximum likelihood may not give a reliable estimate of the 
parameters. On the other hand, Bayesian estimation will converge to maximum likelihood 
method when the amount of data tends to infinity.  
In the results section, the two adaptive prediction methods, Bayesian and maximum 
likelihood, will be compared. Further, these adaptive prediction methods will be compared 
with forgetting factor adaptation to strengthen the results. 
If the values of the parameters of a system change abruptly, periodic resetting of the 
estimation scheme can potentially capture the new values of the parameters. However if the 
parameters vary continuously, slowly with different heuristic, an effective approach is 
popular.  That is the concept of forgetting factor in which older data is gradually discarded in 
favour of more recent information (Ljung, 1999). In Maximum likelihood method, forgetting 
can be viewed as giving less weight to older data and more weight to recent data.  The loss 
function is then defined as follows: 
    ∑    [      ̂   ]
 
 
   
 (5.6) 
where SSE stands for sum of squared errors,       is the measured GTV right before the  -th 
fraction and   is the total number of fractions at the current time for a particular patient, and 
 ̂    is correspondingly modelled GTV and           is called the forgetting factor.  
In addition, these three (Bayesian, Maximum likelihood and forgetting factor) adaptive 
prediction methods will be further compared with the prior prediction method (i.e. only using 
prior population model parameters for prediction with no adaption to individual patients), as 
well as the model fitting results. The intention was that prior prediction established the 
baseline results against which adaptive prediction can improve, and the fitting results gave 
the upper limit of the model accuracy.  
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5.4 Results  
We present the results for Bayesian adaptive GTV prediction using the POP2-EXP model 
(refer to equations (4.2), (4.5) and (4.7) to (4.10)) for this model presented in the Chapter 4. 
Note that the prior distribution of the model parameters was assumed to be log-normal. To 
verify this assumption, Figure 5.1 gives the histograms of the three parameters as calibrated 
to the 25 patients individually. As expected, these parameters do not conform to normal 
distributions, as they must be positive. Instead, Figure 5.1 shows that log-normal distributions 
appear to be good representation of k and  . But for  , almost half of the estimated values are 
close to the upper bound and thus the distribution appears to be bi-modal. Nevertheless, log-
normal distribution was still used for   for its straightforward implementation. The 
histograms also show a large inter-patient variability for all three parameters estimated. 
 
(a) 
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(b) 
 
(c) 
 
Fig. 5.1 Histograms (normalised to pdf) of estimated parameters for the POP2-EXP model, 
and the fitted log-normal distributions; (a) Rate of proliferation (    (b) The linear killing 
effect of radiation (    (c) Rate of clearance (   
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5.4.1 Overall results  
Figures 5.2(a), 5.3(a) and 5.4(a) give the typical results of Bayesian adaptive prediction for 
three patients, whose model fitting results were shown in chapter 4. For clarity, the predicted 
GTV changes are presented for every five fractions of radiotherapy, though the model and the 
prediction were actually updated after each fraction of radiotherapy. The prior predictions 
show similar trend for all patients, since they rely on the similar population parameters which 
indicate that on average, patients are quite responsive to the treatment with decreasing GTV 
over time. (Note that the prior distributions are not exactly the same for different patients, 
because when one patient is to be predicted, it is excluded from the population for calculating 
the prior. This method is adopted to mimic the reality that a particulate patient‘s GTV change 
is not known prior to treatment.) In general, the prior predictions are inaccurate, and for the 
three patients presented they substantially over-estimate the sensitivity to radiotherapy. The 
Bayesian adaption method achieved improved prediction to various extent. For patient 9 (Fig. 
5.2(a)), the model seems to provide satisfactory prediction as early as fraction 5 (28 fractions 
in total). However for patient 6 and 19 (figures 5.3(a) and 5.4(a) , respectively), the 
computational method could not ―foresee‖ a quick drop of GTV somewhere in the middle of 
treatment, and thus the predictions were not as satisfactory until late stage of the treatment. 
Fig. 5.2(b), Fig. 5.3(b) and Fig. 5.4(b) show how the model is updated by re-estimating 
parameters. In Fig. 5.2(b), from day 3 to 40, in Fig. 5.3(b), from day 8 to 23 and in Fig. 
5.4(b), from day 1 to 3,   suddenly drops, whereas   slightly increases and after few 
fractions, it (specifically in Fig. 5.2(b)) stays constant. Thus such low   and high   mean 
rapid reduction of tumour volume. The parameters appears to converge towards the end of 
treatment in the Fig 5.3(b) and Fig 5.4(b). It suggests that at the end of treatment, the model is 
updated with more accurate parameter values. As a results, a better model prediction is 
achieved during last few fractions of radiotherapy treatment.  
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(a) 
 
(b) 
 
 
Fig. 5.2 Bayesian model adaptation for patient no. 9 (minimum RMSE in model fitting); (a) 
gross tumour volume (GTV) as a function of time; (b) re-estimated model parameters versus 
day into treatment 
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(a) 
 
(b) 
 
 
Fig. 5.3 Bayesian model adaptation for patient no. 6 (minimum RMSE in model fitting); (a) 
gross tumour volume (GTV) as a function of time; (b) re-estimated model parameters versus 
day into treatment 
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(a) 
 
(b) 
 
Fig. 5.4 Bayesian model adaptation for patient no. 19 (highest RMSE in model fitting); (a) 
gross tumour volume (GTV) as a function of time; (b) re-estimated model parameters versus 
day into treatment 
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Fig. 5.5(a) shows forgetting factor prediction results by using different values of        
  . The forgetting factor value         = 0.35 provides a better GTV prediction, hence that 
value will be used in forgetting factor prediction method. Fig. 5.5(b) summarises the overall 
prediction results of all 25 patients for Bayesian model adaptation, compared with maximum 
likelihood (ML) adaptation, prior prediction (i.e. no adaptation), model fitting (i.e. no 
prediction) and forgetting factor adaptation. The percentage RMSE is calculated from the 
time of prediction towards the end of the treatment, which is why the RMSEs for model 
fitting and prior prediction change slighly with the number of fractions. It can be seen that 
adaptive prediction methods are useful in terms of reducing errors when compared with prior 
prediction: this happens after 4 fractions for Bayesian and forgetting factor adaptions and 
after 8 fractions for ML adaptation. The improvement in prediction accuracy becomes more 
apparent when more data are available, e.g. the RMSE at 15 fractions is 30.1% for Bayesian 
and forgetting factor adaptations against 44.2% for prior prediction, and at 20 fractions is 
28.0% for Bayesian and forgetting factor adaptation adaptation against 44.3% for prior 
prediction. Bayesian and forgetting factor methods appear to be more reliable than the ML 
adaptation when the number of fractions, thus the amount of an individual patient‘s data, is 
small. When more data become available, Bayesian and forgetting factor adaptation 
converged to the ML method, as expected. Finally, when approaching the last few fractions, 
adaptive prediction methods achieved an accuracy comparable to pure model fitting, e.g. at 
fraction 26, the RMSE for Bayesian and forgetting factor adaptations are 13.0% whilst that 
for model fitting is 11.2%. 
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(a) 
 
(b) 
   
Fig. 5.5 Comparative analysis of adaptive predictions with model fitting and prior prediction 
(a) Forgetting factor adaptation by changing the values of          ,  (b) Quantitative 
analysis of model fitting, Bayesian adaptation, prior prediction, Maximum likelihood 
adaptation and forgetting factor adaptation for 25 patient‘s data (when all GTV scans data of 
patients‘ population is available) 
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5.4.2 Impact of the amount of data on prediction accuracy 
Here we present the results by reducing the number of CT scans, in order to study the impact 
of the amount of GTV measurements on prediction accuracy. The idea of reduction in GTV 
scans data will provide a direction to know whether the predictive performance of Bayesian 
model adaptation depends on number of data points. Further it exemplifies that in the light of 
less GTV data, whether Bayesian model adaptation is still effective for early prediction of 
GTV. The reduction in the number of GTV measurements was simulated in such manner that 
for each individual patient, one GTV scan was made available on Monday every week and 2 
GTV scans on Monday and Thursday respectively. For analysis, GTV prediction of those 
three patients‘ data is presented which has least, median and highest RMSE amongst model 
fitting results. In Fig. 5.6(a), Fig. 5.7(a) and Fig. 5.8(a) show that during first few fractions of 
radiotherapy and in the presence of lack of information, a larger error is present in between 
prediction and patient data. As more information is available, a better model prediction can 
be achieved. Figures 5.6(b), 5.7(b) and 5.8(b) show that how the parameters are modified at 
each fraction of radiotherapy for the better allignment of model prediction with patient data. 
Furthermore Fig. 5.6(b) shows that after first fraction the updated parameter k values drops, 
while   goes up and after it stays constant. It means that GTV predictions are sensitive to 
irradiation. As a result a sudden reduction in tumour volume is occurred. Figures 5.7(b) and 
5.8(b) follow the same trend of parameters values towards converge at the end of treatment as 
it was observed in Fig. 5.3(b) and Fig. 5.4(b) respectively.  
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(a) 
 
(b) 
 
Fig. 5.6 Bayesian model adaptation for patient no. 9 (when 2 GTV  scans data of the patient 
are available weekly); (a) gross tumour volume (GTV) as a function of time; (b) re-estimated 
model parameters versus day into treatment 
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(a) 
 
(b) 
 
Fig. 5.7 Bayesian model adaptation for patient no. 6 (when 2 GTV  scans data of the patient 
are available weekly); (a) gross tumour volume (GTV) as a function of time; (b) re-estimated 
model parameters versus day into treatment 
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(a) 
 
(b) 
 
Fig. 5.8 Bayesian model adaptation for patient no. 19 (when 2 GTV  scans data of the patient 
are available weekly); (a) gross tumour volume (GTV) as a function of time; (b) re-estimated 
model parameters versus day into treatment 
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Fig. 5.9 summarised quantitative analysis of all simulation results, when 2 GTV 
measurements of each individual patient are available weekly. Moreover it describes 
quantitatively the impact of the amount of GTV measurements on the results of model fitting, 
maximum likelihood estimation prediction, prior prediction, forgetting factor adaptation and 
Bayesian prediction results in terms of accuracy.  Further it is seen that during first few 
fractions, Bayesian GTV prediction and forgetting factor adaptation have comparatively 
better predictions than maximum likelihood estimation, but as the data increases, maximum 
posterior estimates and forgetting factor adaptation started to converge towards maximum 
likelihood estimation. At the end, MAP, forgetting factor adaptation and maximum likelihood 
estimation lies on the same line as seen in this figure. Furthermore it indicates that Bayesian 
adaptive prediction results could be improved if more GTV data is available as it is observed 
in Fig. 5.5. 
 
 
Fig. 5.9 Quantitative analysis of model fitting, Bayesian adaptation, prior prediction, 
Maximum likelihood adaptation and forgetting factor adaptation for 25 patient‘s data (when 
two GTV measurements of patients‘ population are available weekly) 
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Fig. 5.10(a), Fig. 5.11(a) and Fig. 5.12(a) follows the same GTV prediction trend as observed 
in Fig. 5.6(a), Fig. 5.7(a) and Fig. 5.8(a) respectively. Due to very limited data (one CT scan 
for GTV measurement per week for each individual patient is available), a higher mismatch 
is present between Bayesian adaptive model prediction and patient data comparatively 
previously explained GTV prediction results. Hence it demonstrates that discrepancy (error) 
could be reduced if more and more GTV data is available. Fig. 5.10(b), Fig. 5.11(b) and Fig. 
5.12(b) show the disparity of the parameters at each fraction of radiotherapy for better 
allignment between model prediction and patient data.  
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(a) 
 
(b) 
 
Fig. 5.10 Bayesian model adaptation for patient no. 9 (when 1 GTV  scan data of the patient 
is available weekly); (a) gross tumour volume (GTV) as a function of time; (b) re-estimated 
model parameters versus day into treatment 
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(a) 
 
(b) 
 
Fig. 5.11 Bayesian model adaptation for patient no. 6 (when 1 GTV  scan data of the patient 
is available weekly); (a) gross tumour volume (GTV) as a function of time; (b) re-estimated 
model parameters versus day into treatment 
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(a) 
 
(b) 
 
Fig. 5.12 Bayesian model adaptation for patient no. 19 (when 1 GTV  scan data of the patient 
is available weekly); (a) gross tumour volume (GTV) as a function of time; (b) re-estimated 
model parameters versus day into treatment 
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Fig. 5.13 presents the quantitative comparison of overall Bayesian adaptive prediction results 
with prior, maximum likelihood estimation, forgetting factor adaptation and model fitting 
results. Due to the availability of one GTV measurement during each week, Bayesian 
adaptive and forgetting factor predictions give high RMSE comparetively to other overall 
Bayesian and forgetting factor adaptive predictions results. Furthermore it indicates that 
Bayesian and forgetting factor GTV predictions provide better results if GTV scan data is 
available more than once a week. Moreover it is observed that MAP and forgetting factor 
adaptation started converging towards maximum likelihood estimation and finally at the end 
of 8
th
 GTV measurement, MAP, forgetting factor and maximum likelihood lies on same 
point. 
 
Fig. 5.13 Quantitative analysis of model fitting, Bayesian adaptation, prior prediction, 
Maximum likelihood adaptation and forgetting factor adaptation for 25 patient‘s data (when 
one GTV measurement of patients‘ population is available weekly) 
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5.5 Discussions 
In this research work, we investigated a Bayesian adaptive modelling approach for early GTV 
prediction during the treatment that will help clinicians to update planning and scheduling 
effectively with updating of model. More recently, the concept of adaptive modelling of 
tumour volume for individual patients has started to emerge. Zhong & Chetty (2014) showed 
that the parameters of a radiobiological model can be more accurately estimated by using 
more data of an individual patient; however they did not explore further to demonstrate 
adaptive prediction of tumour volume. In another study, Brink et al. (2014) reported that 
when the model was developed by using the tumour volumes from the first 2/3 of the 
treatment, its prediction of the remaining 1/3 of the treatment was very good; however the 
model used was not radiobiology-based but an empirical exponential equation. Against this 
background, this chapter reports a new Bayesian adaptation approach with radiobiological 
modelling, for predicting individual patient‘s tumour volume change during conventionally 
fractionated radiotherapy of NSCLC. Hence the following below mentioned main 
observations are considered into account in results. 
The first important observation is the inter-patient variability suggests that a population 
model, which describes some average profile of response to treatment, has limited value in 
the prediction for individual patients. Patient-specific information is needed for personalised 
prediction. In this regard, the presented Bayesian adaption approach can adjust the model and 
prediction based on the patient‘s early response; it can provide significantly improved 
prediction as illustrated in Fig. 5.2(a). 
It should be noted that the model adaptation methods (Bayesian, forgetting factor and 
maximum likelihood) do not give better predictions than the population average at the first 
few fractions when data are limited. This is expected, since the POP2-EXP model has three 
parameters and cannot be reliably estimated by using, e.g. three data points or less. In other 
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words, the patient has not provided sufficient, individual information for the model to adapt 
properly. Nevertheless, the Bayesian and forgetting factor approaches appear to be less 
susceptible to the limited amount of data when compared with the maximum likelihood 
method. Therefore, it is recommended that adaptive prediction should only be considered 
when the number of patient-specific data points is greater than the number of model 
parameters, and the Bayesian and forgetting factor approaches are preferred to the maximum 
likelihood estimation.  This requirement may exclude the application of the adaptive 
prediction method to hypo-fractionation in which only a few fractions of high dose radiation 
are used (e.g. SABR). For example, in figures 5.5, 5.9 and 5.13 it is observed that how MAP 
provides a better GTV prediction results from the start of radiotherapy comparatively to 
maximum likelihood estimation. This is because MAP has priori, whereas Maximum 
likelihood just depends on observation (current GTV information), but as the number of 
fractions of radiotherapy increases the MAP prediction results and Maximum likelihood lie 
on the same line. Furthermore it is analysed that better Bayesian model prediction is achieved 
if more data points (information about GTV) are available as shown in Fig. 5.5, Fig. 5.9 and 
Fig. 5.13 respectively. By comparison it is concluded that Fig. 5.5 provides a better MAP and 
forgetting factor prediction results than remaining two figures due to more availability of 
GTV data. Accordingly MAP and forgetting factor prediction results are appropriate due to 
trade-off between priori and likelihood function from very beginning of radiotherapy 
treatment. 
Apparent tumour growth can be observed for some patients, for example patient 19 
shown in Figure 9. The same phenomenon was seen in our previous modelling study of 
hypofrationated radiotherapy (SABR) of lung cancer (Tariq et al., 2015). As discussed in that 
study, the apparent volume growth could be the result of a number of factors (possibly a 
combination of them), including (i) actual tumour growth, (ii) tumour inflammatory response 
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to treatment, (iii) surrounding normal tissue‘s response to treatment, (iv) uncertainties in 
contouring, and (iv) changes in breathing patter or patient motion. Only the first factor was 
explicitly represented in the model, since it is not possible to distinguish these from MVCT 
images. 
A limitation of the model adaption approach is its reliance on the data obtained during 
treatment. If a particular patient‘s response is very different from the average profile of the 
population, the prediction will need much more data to be adapted properly. The limitation is 
vividly illustrated on patient 19, whose GTV only began to reduce from day 30 (Fig. 5.4(a)). 
Therefore, it is almost impossible to predict that patient 19‘s GTV will eventually shrink only 
by looking at the data prior to day 30. The apparent delay in tumour shrinkage is probably 
due to other patient-specific factors, which are not reflected in the early stage of the 
treatment. Therefore, the possibility of sudden GTV change in later stage of the treatment 
needs to be borne in mind when using the predictions for decision-making. It would be useful 
to identify, as early into treatment as possible, which patients can be well predicted. From 
figures 5.2(a)-5.4(a), it is tempting to hypothesise that (i) if a patient responds early to 
radiotherapy (patient 9), then very good prediction accuracy can be achieved; and conversely 
(ii) if a patient does not respond until about half into treatment (patient 6 and 19), then 
prediction will not be as good. However, this hypothesis does not generalise to all patients in 
the cohort (results not shown). Nevertheless, given the small patient cohort (25 patients), it is 
too early to tell whether this hypothesis is valid or not. This phenomenon also indicates that, 
although model adaptation methods provide improved prediction when compared with using 
population average, they could be further enhanced by including other patient-specific 
factors. These should be further investigated. 
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5.6 Summary 
In this chapter, the results and methodology for Bayesian model adaptation are presented and 
discussed. The main purpose of this work is to develop adaptive modelling approach that will 
improve the early prediction of GTV for each individual patient‘s data during the treatment. 
Further it is presented and discussed that when a new patient data is available then how in the 
start of treatment, tumour response to radiotherapy will be predicted with the help of initial 
GTV and prior. Furthermore the Bayesian GTV prediction results are presented and analysed 
on the basis of least, median and highest RMSE.  It is also discussed that how GTV 
prediction results give a higher RMSE in the first few fractions but as the information surges, 
a better GTV prediction result is achieved. Furthermore the quantitative analysis of 
simulation results is presented by comparison of Bayesian adaptive prediction results with 
prior prediction, model fitting results and maximum likelihood. It is also noticed that how at 
the very beginning of treatment, MAP prediction more depends on prior but as the 
information increases Bayesian adaptive prediction started converging towards maximum 
likelihood and at the end both lies on the same line. Moreover it is also analysed that when 
GTV measurement of each patient is available twice weekly or once weekly then whether 
Bayesian GTV prediction is still effective or not. Consequently maximisation of posteriori 
estimates develop a quantitative framework that will help in personalised treatment.   
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CHAPTER 6 
ADAPTIVE MODELLING AND PREDICTION OF TREATMENT 
OUTCOME 
 
This chapter presents a method for predicting tumour control probability (TCP), a widely 
used endpoint for assessing the treatment outcome of radiotherapy, during the treatment. 
Such predictions could provide valuable information to assist improved treatment planning 
and scheduling. In this chapter, the methodology for TCP modelling and prediction will be 
presented. Due to lack of clinical data, simulation studies will be conducted to demonstrate 
the usefulness of this approach. This chapter concludes with a summary of the adaptive 
modelling and prediction approach.   
 
6.1 Tumour control probability model 
In the past, a lot of studies have been conducted to predict TCP for populations of patients 
before and/or after radiotherapy (Hedman et al., 2013). Nevertheless, the prediction of TCP 
during treatment for individual patients has not been well explored. It should be noted that 
TCP is a probabilistic measure that is applicable for both an individual and a patient 
population – in the former case it reflects the probability that a particular patient‘s tumour 
will be under control, whereas in the latter case it usually measures the fraction of patients 
whose tumours are under control. The capability of prediction of TCP for individual patients 
can help clinicians to timely adjust radiotherapy dose and scheduling, i.e. personalised 
radiotherapy.  
For the prediction of the outcome of radiation treatment it is not enough to determine the 
probability of individual cells to die following irradiation with the prescribed dose. Since the 
goal is to eliminate all malignant clonogenic cells, the probability of remaining clonogenic 
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cells must be determined. Such volume is not the sole determinant of TCP, whereas in theory 
it is the number of clonogenic cells. Hence according to Poisson statistics the tumour control 
probability (TCP) is given by the following expression (Steel, 2002; Bentzen, 1997; Johnson 
et al., 1995; Web & Nahum, 1993; Dawson & Hillen, 2006). 
       {     }                                                           
where      represents the number of clonogenic cells that are still left in tumour volume 
after the completion of radiotherapy treatment.      is the product of clonogenic cells 
density and end volume after the radiotherapy treatment, hence equation (6.1) is further 
simplified as, 
       {      }                                                              (6.2) 
In equation (6.2),   stands for clonogenic cell density, while      is the end tumour volume 
after the radiotherapy treatment. 
Equation (6.2) provides a connection between the end-treatment tumour volume and TCP 
through a model parameter, the clonogenic cell density, which needs to be estimated from 
data. The clinical data would consist of the end-treatment tumour volume of a patient 
population, and each patient‘s outcome (either under control or not) assessed at a particular 
time point (e.g. one year post-treatment). Although   varies from one patient to another in 
reality, such clinical data would not be sufficient to estimate patient-specific  . Therefore, 
this research adopts the assumption of a fixed   across all patients, which has been used in 
related modelling studies (South et al., 2009). With this assumption,   can be estimated from 
the data of a population of patients including their end-treatment volume (      , where   is 
patient number) and corresponding outcome (  , where      denotes tumour under control 
and      out of control). Specifically, the maximum likelihood method can be used to find 
the optimum   by using the interior point method (MATLAB Optimisation Toolbox, 
Fmincon) that fits the data (Keall and Webb, 2006):  
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    {  ∑        ∑    [     (        )]            }                          (6.3) 
It is worth noting that the reported value for clonogenic cells density is around     
             for un-treated tumours (Steel, 2002; South et al., 2008, 2009; Web & Nahum, 
1993). However, this value should not be used as a reference for end-treatment because for 
any clinically detectable tumour volume (e.g. > 1   ), equation (6.2) will give an effectively 
zero TCP. In addition, the estimated   is usually not a whole number, which means that   
should not literally interpreted as the number of cells per unit volume; rather it should be 
regarded as a model parameter linking volume to TCP.  
 
6.2 Adaptive prediction of TCP 
Equation (6.2) provides the basis for adaptive prediction of TCP during the course of 
radiotherapy. The Bayesian adaptation method presented in Chapter 5 can be used to predict 
GTV from the first fraction of radiotherapy till the end, through re-estimation of model 
parameters when new volume measurements become available. This predicted end-treatment 
GTV can thus be fed into equation (6.2) to provide a prediction of TCP. In a sense, this is a 
hybrid population-individual approach, since the volume prediction is personalised but the 
linkage between volume and TCP is population-based (fixed   for all patients).  
 
6.3 Simulation study 
Due to the lack of clinical data with both tumour volume and treatment outcome, this 
research has adopted a simulation approach to demonstrate the usefulness of the proposed 
adaptive TCP prediction approach. First, a review of clinical studies was conducted to 
identify clinically relevant TCP values. Subsequently, a large population (1000) of virtual 
patients were simulated in two steps: (i) the simulation of tumour volume during the course 
of radiotherapy, and (ii) the simulation of their clinical outcome so the population TCP 
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matches what were reported in the literature. Finally, the method for the evaluation of TCP 
prediction performance is discussed. The simulation study was focused on NSCLC for the 
two clinical datasets used in this thesis are all from NSCLC patients. 
 
6.3.1 Clinical studies of NSCLC in relation to tumour local control  
Table 6.1 summarises the literature reported fraction of local control of NSCLC under 
different radiotherapy treatment regimes, at one and two years post-treatment. Some studies 
also reported overall survival in addition to local control; however only local control is used 
because it is regarded the most directly related to response to radiotherapy (Huang et al., 
2010; Sridharan and Warde, 2012)  (e.g. overall survival also relates to metastasis which is 
not the target of radiotherapy). Significant variability in outcome can be observed across 
clinical studies, and different studies used different treatment regimes (e.g. conventional 
radiotherapy, stereotactic ablative radiotherapy (SABR) and intensity modulation radiation 
therapy (IMRT) where the protocols are also different). As Willner et al., (2002) reported the 
study of 165 NSCLC patients under conventional radiotherapy treatment to evaluate the 
influence of total dose on tumour volume in term of local control and survival. According to 
Willner report, year 1 and year 2 local control rates were 50% and 30% respectively. 
Whereas, Lagerwaard et al., (2011) reported the details of 177 patients of stage 1 NSCLC 
who were treated with SABR in between 1993 to 2010.  In this study, the two year outcomes 
in term of tumour local control were 93% and 84.7% respectively. Nevertheless, a 
randomised controlled trial for 225 patients in locally advanced NSCLC under treatment of 
conventional radiotherapy by taking 2 Gy for 30 fractions was conducted from 1990-1995 in 
UK (Saunders et al., 1999). The reported local control of tumour for year 1, year 2 and year 3 
were 45%, 20% and 16 % respectively. 
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Table 6.1 Summary of binary end points for NSCLC under radiotherapy treatment 
Number of 
patients 
Radiotherapy 
regime 
One year 
tumour 
local control 
Two year tumour 
local control 
References 
165 NSCLC Conventional 
radiotherapy 
50% 30% (Willner et., 
2002) 
177 NSCLC SABR 93% 84.7% (Lagerwaard et 
al., 2011) 
225 NSCLC Conventional 
radiotherapy 
45% 20% (Saunders et 
al., 1999) 
39 NSCLC IMRT 73% 58% (Sura et al., 
2008) 
 
From the period between 2001 and 2005, a population of 39 patients of NSCLC with 
stage IIIB were reported with their treatment outcomes that were treated by IMRT (Sura et 
al., 2008). Sura et al., (2008) reported one year local control for stage IIIB was 73% and 58% 
for two years. These studies provide a significant help regarding treatment outcome. As the 
tomotherapy patients‘ data has a good match with the reported study of Sura et al., (2008), in 
term of total/ fractionated dose of radiotherapy, patients‘ population and tumour stage. 
Therefore the treatment outcome presented their study will be considered for analysis of TCP 
prediction. 
 
6.3.2 Simulation of virtual patients’ data 
Initially, two population exponential growth model for tumour repopulation and LQ model 
for radiotherapy effects of tumour cells killing ( chosen for tumour modelling studies on the 
basis of AIC criteria) was used to estimate population parameters for a locally advanced 
NSCLC patients data. These modelling studies have already been discussed in chapters 4 and 
5. After this, plotted the histograms with their corresponding pdfs of clinical data 
(tomotherapy patients‘ data) and estimated parameters of tumour dynamic model that show 
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the distribution of population parameters and tomotherapy data. The pdfs of population 
parameters has been presented in chapter 5, whereas pdf for tomotherapy patients‘ data will 
be presented in results section of this chapter. As the pdfs of estimated parameters and 
tomotherapy patients‘ data show log-normal distribution, hence log-normal distribution for 
population parameters and clinical data will be used. Now with the help of reported study of 
Sura et al., (2008), a simulation based study is carried on to generate GTV dynamics and their 
treatment outcome (local control or not) for1000 virtual patients. For this simulation study, a 
log normally distributed random variable is generated after re-adjusting the clonogenic cell 
density value with the published data (Sura et al., 2008) in relation to tumour local control 
end point and by using mean and standard deviation of population parameters and initial 
GTVs of tomotherapy data. Since, the generated GTV data didn‘t match with the clinical data 
in term of error in clinical GTV. Hence to overcome this discrepancy in simulated data 
(virtual data), an additional parameter noise (ε) was included in tumour dynamics model that 
having zero (0) mean and relative standard deviation for 10% of corresponding GTV. 
Subsequently, after addition of noise parameter in dynamic model, virtual patients‘ data will 
be generated by simulation. 
 
6.3.3 Evaluation of prediction performance 
The predictive performance of adaptive modelling for TCP prediction will be quantitatively 
analysed by RMSE. The population TCP will be predicted with the help of actual TCP and 
prior TCP. The prior TCP is considered 73% and 58% for one and two year tumour local 
control for all virtual patients‘ data respectively. Now by comparing personalised adaptive 
TCP prediction results with the predicted TCP approach results by prior TCP and it can be 
concluded that why simulation based personalised adaptive TCP prediction has a great impact 
in measurement of better treatment outcomes. Furthermore, for the measurement of noise 
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impact on TCP prediction, a sensitivity analysis will be done by considering the noise 10%, 
20%, 30% and 40% respectively. Moreover considering if CT imaging for GTV measurement 
is available once or twice a week and what affects it has on TCP prediction. Process flow 
chart of adaptive modelling for TCP prediction (Sections 6.1, 6.2 and 6.3) are presented in 
Fig. 1. 
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Fig. 6.1 Process flow chart of adaptive modelling for TCP prediction 
 
 
 
Estimation of population parameters 
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re-adjusting clonogenical cell density 
(𝜌) to predict the required outcome of 
tumour local control 
Estimate the clonogenic cells density 
with the help of simulated outcome by 
using maximum likelihood 
Estimate the GTV prediction from 1
st
 
fraction of radiotherapy till to end 
fraction of simulated patient data by 
using MAP 
 
Make a link between GTV prediction 
with TCP model (using estimated ‗𝜌‘) to 
predict TCP for an individual patient 
Quantitative analysis of adaptive 
modelling for TCP prediction in-terms of 
RMSE 
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6.4 Results 
In this section results are presented in terms of log-normally distributed initial GTVs of 
tomotherapy patients‘ data, Bayesian prediction of GTV, TCP prediction, effectiveness of 
TCP prediction, sensitivity analysis of noise and by decreasing the number of GTVs 
measurement and  the impact on the effectiveness of TCP prediction will be analysed. First, 
the results are presented regarding histograms fitted with pdf for initial GTVs. The main 
objective of plotting this histogram and pdf is to know the distribution of initial GTVs. As 
these initial GTVs will be used in simulation based study to predict the outcome of 
radiotherapy and in parallel to generate the gross tumour volume with respect to time, these 
simulation results will later be used in TCP prediction of each individual virtual patient. 
Hence it is important to find out the accurate distribution of initial GTVs, because we will use 
this prior (initial GTVs) information to generate the 1000 virtual patients‘ data (GTV with 
respect to time) and corresponding outcomes (i.e., either tumour is local control or not). Fig. 
6.2 shows that GTVs are log-normally distributed. Consequently, with the help of log-
normally distributed prior (initial GTV and population parameters), further by using reported 
study of Sura et al., (2008), virtual patients‘ data are generated. 
 
 
 
118 
 
 
Fig. 6.2 Histogram (normalised to pdf) of initial GTV for the tomotherapy patients‘ data, and 
the fitted log-normal distribution  
 
Next with the help of maximum likelihood estimation technique, the TCP model parameter 
(clonogenic cells density) is estimated by considering one and two years tumour local control 
respectively. The estimated values of clonogenic cells density are presented in the table 6.2. 
 
Table 6.2 Summary of estimated values of clonogenic cells density 
 
   
     
   
 
  
One year tumour local control 0.0063 
Two year tumour local control 0.018 
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In table 6.2, the estimated values of   for one year tumour local control is 0.0063 (
     
   
), 
similarly estimated values of   for two years local control is 0.018 (
     
   
). As TCP is not 
solely dependent on GTV, but    is also an important factor to consider. Hence the estimated 
values of   will be used for TCP predictions. The main objective of this study is to develop 
an adaptive modelling approach for TCP prediction for each individual patient before each 
fraction of radiotherapy that will aid clinicians in better treatment planning and scheduling 
(i.e., dose optimisation). Hence for this purpose results for Bayesian GTV and TCP 
predictions are presented. However these results are chosen on the basis of least, median and 
highest in RMSE during model fitting amongst all simulation results. Fig. 6.3(a) exemplifies 
the GTV prediction during each fraction of radiotherapy. Furthermore, this figure shows that 
when model is updated during first two fractions of radiotherapy by MAP, a large error 
between modelling prediction and simulated GTV is obtained during first few fractions of 
radiotherapy. However, as the information (number of fractions) increases, model predictions 
start getting closer to actual virtual patient data. Hence MAP provides a better model 
prediction that will help in better TCP prediction.   Moreover, the linking of GTV prediction 
with TCP model is used to predict TCP. Hence, fig. 6.3(b)   provides TCP prediction results 
for one and two years respectively. Also this figure shows actual and model predicted TCP 
for one year and two years tumour local control. However actual TCP is measured when end 
simulated volume is used, whereas, model TCP is measured when end model predicted 
volume is used. Therefore the better prediction of TCP depends on better GTV prediction. 
Hence, as GTV prediction results after few fractions of radiotherapy are getting better and in 
parallel TCP provides an appropriate prediction results for one and two years 
correspondingly. Fig. 6.4(a) illustrates the Bayesian GTV prediction, however the results of 
first five fractions of GTV prediction show more radio-resistant and afterward it becomes 
more radio-sensitive. This is happened due to limited information (i.e., just on basis of prior 
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information and CT scan of first GTV).  But as the model is updated by re-estimation model 
parameters, this discrepancy (error between data and model prediction) started decreasing. 
However Fig. 6.4(b) presents TCP prediction results for one and two years accordingly for 
the same virtual patient data. Fig. 6.4(b) indicates a higher error in between actual and model 
predicted TCP for one and two years respectively during first few fractions of treatment and 
the same discrepancy trend is already seen in GTV prediction results. Hence as GTV 
prediction result is improving, then we can see that error between actual and model predicted 
TCP started decreasing. Consequently, this demonstrates the importance of appropriate 
prediction of GTV for TCP prediction. Fig. 6.5(a) presents GTV predictions and it reveals 
that just after few fractions, model start predicting appropriate GTV. However, Fig. 6.5(b) 
presents the TCP predictions for one and two years and follows the same trend of TCP 
prediction as seen in figures 6.3(b) and 6.4(b) accordingly. 
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(a) 
 
(b) 
 
Fig. 6.3 GTV as a function of time (least RMSE in model fitting); (a) GTV prediction by 
model; (b) TCP prediction as a function of time 
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(a) 
 
(b) 
 
Fig. 6.4 GTV as a function of time (median RMSE in model fitting); (a) GTV prediction by 
model; (b) TCP prediction as a function of time 
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(a) 
 
(b) 
 
Fig. 6.5 GTV as a function of time (highest RMSE in model fitting); (a) GTV prediction by 
model; (b) TCP prediction as a function of time 
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Fig. 6.6 determines the predictive performance of TCP predictions by measuring overall 
RMSE for all virtual data. Furthermore it shows RMSE for one and two year TCP 
respectively. By looking at this figure, we observed that during first four fractions, RMSE in 
one year TCP varies from 0.27 to 0.39 and similarly for two year TCP fluctuates from 0.19 to 
0.36. This happens when model is updated in the presence of lack of information, and as a 
result it suffers with a big discrepancy (error) in GTV prediction and patient data. Though 
GTV prediction is linked with TCP prediction that is why RMSE in TCP for one year and 
two year TCP during first few fractions is high. But as the information upsurges, the error in 
GTV prediction as well as RMSE in TCP started decreasing. In brief, TCP can be updated 
during the treatment, when the tumour response (volume) is assessed by imaging. Hence this 
adaptive modelling approach for TCP prediction is a quantitative framework that will have 
rational values for clinicians to optimise the radiotherapy treatment for better outcomes.  
 
Fig. 6.6 Overall RMSE in TCP 
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 Further by judging the predictive efficacy of adaptive modelling for TCP predictions 
with population TCP model, the prior TCP for one and two years is considered 0.73 and 0.58 
respectively taken from the published report (Sura et al., 2008). Now by assuming this prior 
TCP is constant for all virtual data in population TCP model. Hence by finding RMSE in 
population TCP model, it is observed that RMSE in population TCP for one year will be 
0.39, whereas for two year it will be 0.27. Therefore by comparing efficacy of population 
TCP with personalised adaptive TCP model, it is concluded that personalised adaptive TCP 
prediction is far better than population TCP prediction as shown in Fig. 6.6. Consequently, 
individualised adaptive TCP modelling technique is a better tool for TCP prediction. 
POP2-EXP model is used for generating virtual patients‘ data with treatment outcome. 
Moreover the same model is used for GTV and TCP prediction. Hence if noise is not 
included in virtual patients‘ data, then POP2-EXP will provide pretty much same GTV and 
TCP prediction results. Further it does not measure underlying dynamics in prediction. For 
these reasons, noise is comprised in simulation data. As noise is the part of data, therefore it 
is highly important to measure the effects of noise on the predictive performance of TCP. 
Hence, as a result, noise sensitivity analysis is conducted. In Fig. 6.7, sensitivity analysis of 
noise is done by considering 10%, 20%, 30% and 40% noise correspondingly. It is observed 
that as noise level increases, the efficacy and robustness of TCP prediction decreases. Further 
it is noted that for 10% noise, model predicts an appropriate TCP. Whereas when noise level 
increases (i.e., 20%, 30%, %40 and so on), the quality of predictive performance of TCP 
starts decline. It means that when data has a 100% level of noise, the deterministic structure 
for TCP prediction is lost completely and it becomes impossible to predict successfully.   
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Fig. 6.7 Sensitivity analysis of Noise 
Now determine the predictive performance of TCP, when less number of GTVs 
measurements is available weekly. This type of study provides a bigger picture of TCP 
prediction by considering various aspects. Hence for this purpose, TCP prediction is 
classified on the basis of once and twice a week availability of CT scans for GTV 
measurement. However, Fig. 6.8 validates the overall RMSE in one and two years TCP 
respectively, when GTV is measured twice a week. From the figure, it is observed that during 
first few fractions, even in one year or two years, TCP, RMSE is high. But after that it started 
shrinking. Finally, due to updating of model after each fraction of radiotherapy, RMSE goes 
down to 0.16 for one year TCP and similarly for two year TCP, it reduces to 0.9. Overall this 
TCP prediction is in good range, but it can be further improve if more GTV data is available 
as seen in Fig. 6.6. Fig. 6.9 shows RMSE in TCP predictions for one and two years 
consistently when GTV is measured once a week. . As in this study, just few CT scans of 
GTV are considered. Hence RMSE in TCP is higher than Fig. 6.8 and Fig. 6.6. Consequently, 
it indicates that more number of GTV data is required for better TCP prediction. 
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Fig. 6.8 Overall RMSE in TCP when GTV is measured twice weekly (Monday/ Thursday) 
 
  
Fig. 6.9 Overall RMSE in TCP when GTV is measured weekly (every Monday) 
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6.5 Discussions 
It is important to note that as TCP prediction is linked with Bayesian GTV prediction,  
appropriate GTV prediction gives an applicable TCP prediction and vice versa. Further it is 
seen that during first few fractions of radiotherapy, GTV prediction exemplifies a higher error 
between virtual patient data and model prediction. This is due to limited information 
regarding GTV, but as the information surge, a better Bayesian GTV prediction is achieved. 
Hence the same trend is observed in TCP prediction as well. It means that during first few 
fractions of radiotherapy due to bad prediction of GTV, a high RMSE in TCP is obtained. But 
in later fractions of radiotherapy, a better TCP prediction is attained due to suitable GTV 
prediction.  
Secondly it is perceived that personalised adaptive TCP prediction provides a better 
effectiveness of treatment due to momentous reduction in RMSE in TCP as the number of 
data points (CT scans of GTV) surge. Furthermore it is noticed that TCP is usually calculated 
after the treatment. Hence by comparing TCP population model (on the basis of prior TCP) 
with individualised adaptive TCP prediction model, it is observed that TCP individualised 
model have significantly less RMSE in TCP predictions than TCP population modelling 
approach. Furthermore, RMSE in TCP for personalised modelling start decreasing when 
model is updated after each fraction of radiotherapy. Consequently, adaptive modelling for 
TCP is an appropriate choice that could assist oncologists to do better treatment planning and 
scheduling.  
Thirdly it is discerned that by increasing the noise level decreases the quality and 
robustness of TCP prediction and vice versa. Fourthly it is noticed that GTV/ TCP 
predictions depend on GTV data. Hence by increasing or decreasing the GTV scans, a good 
or bad GTV/ TCP prediction will be achieved. Furthermore it is concluded that research work 
have certain limitation those are as follows: 
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 No consideration of pre-treatment information, like pathology, staging, age, 
smoking history, etc. 
 GTV is only reliably measurable for certain sites, in particular the lung; other 
sites may need PET-CT 
 TCP prediction approach need to be tested on real patient data 
 Usage of the same model for simulation and GTV/TCP prediction 
 Assuming   is fixed for all patients‘ data 
 
6.6 Summary 
This chapter is mainly about adaptive modelling and tumour control probability prediction. 
The main idea of this research is the prediction of TCP during the treatment that helps 
clinicians for prognosis purposes and modification of treatment. Hence for the achievement 
of this research objective, firstly with the help of prior (population parameters plus intial 
GTVs of tomotherapy patients‘ data), simulate 1000 virtual patients by using POP2-EXP 
model for tumour growth and LQ model for radiotherapy effects, and after readjusting 
clonogenic cells density, the require outcome (with the help of published data, Sura et al., 
2008) of tumour local control are predicted.  
Secondly TCP model parameters (clonogenic cells density) are estimated by using 
maximum likelihood estimation. Thirdly Bayesian adaptive GTV is predicted from first 
fraction of radiotherapy till to end. Fourthly for the prediction of TCP for an individual 
patient, GTV prediction is linked with TCP model. Finally the prediction performance is 
evaluated quantitatively (RMSE). Furthermore the impact of GTV data on TCP prediction is 
analysed by increasing and deceasing GTV data.  
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CHAPTER 7 
CONCLUSIONS AND FUTURE WORK 
 
Firstly the focus of this thesis was to develop a mathematical model that is appropriate to 
describe tumour volume change measured during radiotherapy by considering a trade-off 
between model fitting and complexity. Secondly the focus was to apply the Bayesian 
adaptive modelling approach and proposed model, to predict tumour volume change at each 
fraction of treatment for each individual patient. Thirdly the emphasis was to integrate the 
tumour volume prediction with tumour control probability (TCP) model to predict TCP at 
each fraction of radiotherapy. Hence the main purpose of above mentioned focussed areas 
was early prediction of tumour-volume change undergoing treatment for each individual 
patient that will help clinicians to do better personalise planning and scheduling for effective 
treatment. However prediction of TCP (treatment outcome) during the treatment can be used 
for prognosis purposes and the adjustment of treatment. The contributions of this thesis, and 
recommendations for future research, are presented in this chapter.  
 
7.1 Summary of contributions 
The main contributions of this thesis are now summarized chapter by chapter. 
 Chapter 4: A large variety of mathematical models have been developed in an attempt 
to describe and predict how tumour volume changes over time. But in all those 
modelling studies, tumour-volume is measured before and after the treatment. Hence 
less attention has been made in modelling studies to measure tumour-volume 
dynamics during the treatment. Therefore chapter 4 presents the modelling study of 
tumour-volume dynamics during the treatment. For this modelling study we analysed 
two different sets of clinical data, one data contained 11 patients of early stage 
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NSCLC under SABR treatment and other comprehended 25 patients of late stage 
NSCLC under tomotherapy. Firstly to examine the feasibility of mathematical models 
for the measurement of tumour-volume dynamics during treatment, six different 
models (POP2-EXP, POP1-EXP, POP2-LOG and POP1-LOG,) were explored. These 
explored models could deliver valuable information for each individual patient 
response to radiotherapy (SABR and tomotherapy). Further models are calibrated for 
each individual patient under SABR by using maximum likelihood estimation.  The 
results demonstrate that relatively simple models are adequate in modelling tumour 
volume dynamics. In addition, a rigorous model selection (AIC and AICc criteria) 
methods are applied to help decide the most appropriate model, given the available 
data. The results suggest that the POP2-EXP model (two populations of tumour cells, 
living and dead, with exponential tumour growth) appears to be an appropriate choice 
for modelling GTV dynamics of NSCLC patients treated by SABR. Furthermore 
same models and methodology has been used for patients‘ data under tomotherapy. 
From the results it is concluded that POP2-EXP is an appropriate model choice for 
GTV modelling of each individual patient during tomotherapy treatment. Further 
during the research of this chapter it is noted that it is possible to model the whole 
data of SABR and tomotherapy patients. However in term of population approach, it 
was observed that a large of patients‘ population is required to determine population 
parameters. Whereas SABR patients have a small number, hence it is not possible to 
find out population parameters. However, tomotherapy patients‘ data has a large 
number; therefore it is conceivable to find out population parameters. In chapter 5 and 
chapter 6, the estimated population parameters are used as priori information. Overall, 
results indicated that POP2-EXP is feasible to use for the modelling tumour-volume 
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dynamics during treatment in clinical environment. This work has been published in 
(Tariq et al., 2015). 
 Chapter 5: The objective of this chapter is to develop adaptive modelling approach 
that explores the feasibility of timely predicting tumour-volume change during 
radiotherapy for locally advanced NSCLC of each individual patient. As parameter 
estimation and identification are an essential step in the development of mathematical 
models that describe the behaviour of physical processes. The best parameters are 
estimated in order to be used in the model for predictive purposes at other conditions 
where the model is called to describe process behaviour. Hence this chapter firstly 
presents population averaged parameters (the prior) that are estimated from 25 
patients‘ population data with the help of POP2-EXP model treated under 
tomotherapy and presented in chapter. Secondly it signifies the Bayesian model 
adaptation for the treatment of individual patient by using maximum a posteriori 
estimation (MAP) method. In Bayesian adaptation model (MAP), it is observed that 
when model is updated by re-estimating parameters at each fraction of radiotherapy, 
the error between model prediction and patient data is started decreasing. It means 
that when a new patient comes for treatment, then patient volume is predicted just on 
the base of population parameters (priori), but during the treatment, model is updated 
when GTV data is available, hence model becomes more and more customised 
(personalised) for a specific patient and as a result, the prediction becomes more and 
more accurate. The effectiveness of the Bayesian adaptation model was tested on data 
from 25 patients by using cross validation technique. Moreover, for quantitative 
analysis of model prediction, %RMSE is measured by comparing prior prediction 
results, model fitting results, maximum likelihood results, forgetting factor adaptation 
and Bayesian adaptive modelling results at each fraction of radiotherapy for patients‘ 
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population model which shows how the MAP approach is effective. Further, same 
quantitative analysis is done by decreasing GTV measurement and it is observed that 
due to less number of GTV measurements (as seen in SABR patients in chapter 4), we 
did not get better MAP prediction as compare to higher number of GTV data.  Hence 
this research work is a quantitative framework of personalised tomo-therapy treatment 
for cancer patient and it can help clinicians in better treatment planning and dose 
scheduling for treatment efficacy. This work has been published in (Tariq et al., 
2016). 
 Chapter 6: As usually TCP is measured after the treatment, and no research has been 
done for TCP prediction during the treatment. However prediction of TCP during the 
treatment could help oncologists to do better treatment planning and dose scheduling 
by reducing the side effects and enhance the benefits for individual patient. Hence in 
this chapter a lot of emphasis has been put on TCP prediction during the treatment. 
For this purpose, a simulation based study has been conducted for TCP prediction. 
Hence TCP is predicted for virtual patients‘ data to make a link of GTV prediction 
with TCP model. It is observed that during first few fractions, GTV prediction and 
patient‘s data has high mismatch and similarly TCP has a high discrepancy in actual 
TCP and predicted one. But as the information surge, the RMSE in GTV prediction 
drops and in parallel due to linkage of GTV prediction with TCP prediction, hence 
error between actual TCP and predicted one start lessening. As a result, a better TCP 
prediction result is achieved. Further, to measure by comparing the effectiveness of 
personalised adaptive TCP prediction with population model for TCP, it is observed 
that adaptive TCP prediction has more effective results than patient population TCP 
model. Furthermore, by decreasing the GTV data and observed the results as 
increased in RMSE in GTV/ TCP prediction. It means that better GTV/ TCP 
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prediction depends on more and more GTV data. Overall, this work shows an 
adaptive modelling approach for TCP prediction that helps clinician for prognosis 
purposes. This chapter has a complete research paper in the area of ‗adaptive 
modelling and TCP prediction for individual patient: a simulation based study‘. Our 
plan is to submit this research after PhD viva. 
 
7.2 Future research directions 
This thesis has demonstrated the feasibility of appropriate model, Bayesian adaptive GTV 
prediction and adaptive modelling for TCP prediction for each individual patient during the 
treatment of SABR and tomotherapy that is a relatively new area of research. However, there 
are still many open issues that necessitate further in-depth investigation. A number of 
possible future research directions are given below.  
 Future research is focused on extending the adaptive prediction of tumour 
volume, which is usually a secondary end-point, to primary treatment end-
points such as tumour control probability. Moreover, there is a possibility to 
explore how other factors, in addition to tumour volume, could be included in 
the modelling framework to further improve the prediction accuracy. To this 
end, advanced functional imaging, for example positron emission 
tomography-computed tomography (PET-CT), is a promising technique. 
Tumour heterogeneity seen on functional imaging is likely to provide key 
information about other factors, for example proliferation, quiescent, necrosis, 
etc., apart from GTV. Hence in the presence of such information, by using the 
heterogeneous growth of tumour model framework that is already presented in 
chapter 2, may be further improved model fitting and prediction accuracy. It is 
known that tumour control probability is determined by the living tumour 
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cells, which cannot be differentiated from those killed by radiation on volume 
measurements alone. Tumour heterogeneity seen on functional imaging is 
likely to provide key information for the prediction of treatment outcome that 
will help clinicians to do better treatment planning and scheduling, and this 
will be explored in future.  
 In this research, a simulation based study is developed for TCP prediction due 
to un-availability of a large number of real patients‘ data. However, in future, 
we could extend the TCP prediction model to real data, and validate that with 
sufficiently large number of patients. As in this research, a personalised 
tumour volume prediction was integrated with a population TCP model, to 
predict TCP. Hence this research have a potential future direction in the area 
of building a personalised TCP model  framework (by estimation of ρ for each 
individual patient) that then integrate with individualised GTV prediction, for 
personalised and timely planning and scheduling of radiotherapy. 
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APPENDIX-I 
 
Table 3.2 SABR patients‘ data (subscript denoting patient number) 
     
      
     
      
 
     
      
 
     
      
 
     
      
 
     
      
 
     
      
 
     
      
 
     
      
 
     
      
 
      
      
 
      
      
 
0 2.99 1.78 17.85 7.63 28.69 11.2 6.58 16.36 7.27 26.81 12.06 
2 2.37 1.8 19.78 7.66 26.83 8.21 6.63 15.49 - 25.39 11.91 
4 2.35 1.48 - - - 8.18 6.72 - 5.99 23.57 - 
5 - - 18.5 7.6 22.86 - - 15.15 - - 11.79 
6 - - - - - 4.76 - - - - - 
7 2.9 1.42 17.68 6.7 22.15 - 6.41 14.07 6.05 20.5 11.73 
8 - - - - - 3.68 - - - - - 
9 2.16 1.38 16.8 6.72 18.74 - 5.45 13.42 5.91 18.4 11.17 
11 2.11 1.14 - - - - - - 5.68 - - 
14 2.19 1.31 - - - - - - - - - 
16 2.01 1.25 - - - - - - - - - 
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APPENDIX-II 
Table 3.3 Tomotherapy patients‘ data (subscript denoting patient number)  
   
      
     
      
 
   
      
     
      
 
   
      
     
      
 
   
      
     
      
 
   
      
     
      
 
   
      
     
      
 
   
      
     
      
 
0 23.39 0 830.79 0 201.7 0 250 0 108.43 0 484.6 0 572.39 
1 23.09 1 819.81 5 188.4 1 250 1 111.43 1 477.7 1 570.71 
2 23.07 2 811.1 6 182.8 2 236.6 2 106.98 2 487.5 2 568.12 
3 21.34 5 798.85 7 181.6 3 236.7 5 103.65 3 492.9 4 564.49 
6 19.28 6 738.47 8 170.8 6 227.1 6 99.61 6 467 5 546.31 
7 18.53 7 701.27 9 168.1 7 238 7 100.72 7 460.4 8 540.1 
8 17.75 8 679.67 14 160.6 8 239.4 8 98.15 8 490.9 9 539.82 
9 16.59 9 675.68 15 151.3 9 244.5 9 103.26 9 472.6 10 531.48 
14 15.57 12 625.38 16 144.9 10 241.3 12 102.86 10 483.2 11 518.9 
15 13.59 13 618.56 20 125.4 13 241 13 103.27 13 480.9 12 513.79 
- - 14 605.32 21 123.3 14 236.4 14 100.77 14 476.8 15 505.69 
- - 15 595.17 22 97.5 15 236.8 15 102.74 15 482.4 16 485.14 
- - 16 582.73 23 85.2 16 233.3 16 99.88 16 471.1 17 553.53 
- - 19 570 26 65.6 17 230.5 19 93.3 17 461.7 18 475.26 
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- - 20 565.71 27 61.6 20 232.1 20 96.1 20 461.9 19 468.36 
- - 21 556.9 28 62.8 21 220.5 21 94.79 21 451.7 22 446.48 
- - 22 552.89 29 56.7 22 210.5 22 91.44 22 450.9 23 419.17 
- - 23 537.16 30 59 23 164 23 88.36 23 455.3 25 404.42 
- - 26 518.91 33 55.2 24 177 34 64.69 24 406.4 26 393.29 
- - 34 510.56 41 53.7 27 157.8 35 66.55 27 397 - - 
- - 35 509.72 42 56.1 28 169.4 36 71.62 28 392.1 - - 
- - 36 504.83 43 53.6 29 176.3 37 61.37 29 376.2 - - 
- - 37 503.42 44 46.1 30 171.8 41 67 30 356.7 - - 
- - 41 448.29 47 39.7 31 161.3 42 66.01 31 348.4 - - 
- - 42 477.93 49 44.6 35 159.3 43 65.25 36 344 - - 
- - 43 470.22 50 45 36 155.6 44 63.71 37 330.14 - - 
- - 44 458.41 51 36.9 43 143 47 62.14 38 335.4 - - 
- - 45 445.02 55 40 44 146.8 48 66.22 42 323.16 - - 
- - 49 416.35 56 36.1 45 141.4 49 63.98 43 369.4 - - 
- - 50 415.84 57 25.6 48 133.2 50 64.02 44 374.9 - - 
- - 51 414.76 - - 49 132 - - 45 386.14 - - 
- - 52 414.1 - - 50 141.2 - - - - - - 
- - - - - - 51 138.8 - - - - - - 
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Table 3.4 Tomotherapy patients‘ data (subscript denoting patient number) 
   
      
     
      
 
   
      
     
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
0 177.41 0 82.98 0 151.532 0 99.9 0 50.5 0 155.8 
1 174.85 1 80.2 1 148.99 9 82.8 3 48 4 152.7 
2 173.9 2 78.92 2 145.58 10 82.3 4 47.6 5 149.8 
5 170.87 3 76.51 5 143.5 13 86.1 5 46.8 6 146.5 
12 149.44 5 78.54 6 138.79 14 86.2 6 46 7 142.5 
13 142.21 6 75.72 7 135.2 15 84.6 7 42.4 8 140 
14 135.76 7 75.06 9 132.59 16 82.7 12 41.8 11 138.9 
15 131.21 8 72.98 12 130.22 17 82.2 13 41.7 12 139.8 
32 129.4 12 70.63 13 128.07 20 76.9 14 42 13 135.1 
33 121.96 13 67.19 14 125.89 21 75 15 42.2 14 132.3 
36 119.34 14 65.99 15 123.64 22 72.8 18 41.9 15 125.9 
37 117.72 18 59.45 16 119.12 23 65.7 19 40.5 18 114.2 
38 114.88 20 62.6 19 117.58 24 62.7 20 39.4 19 116.5 
39 113.16 21 59.91 20 115.24 27 55.3 32 35.4 20 112.9 
40 105.35 22 58.7 21 112.79 28 52.8 33 35.3 21 103.1 
- - 25 56.76 22 111.8 29 51.6 34 37 22 98.3 
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- - 26 55.1 26 106.89 30 54.2 35 35.7 26 98 
- - 27 52.15 27 103.77 34 54.3 36 35.4 27 95.4 
- - 28 50.8 29 100.69 35 52.6 39 35.2 28 88.8 
- - 29 51.56 34 99.18 36 52.2 40 34.6 29 86.9 
- - 32 50.4 35 100.67 38 44.6 41 33.9 32 91.5 
- - 33 49.45 36 98.81 49 37.2 42 32.9 33 92.9 
- - 34 48.32 37 97.53 50 37.7 43 32.8 34 91.1 
- - 36 46.75 38 96.98 51 33.9 46 33.3 35 84.6 
- - 39 44.85 41 95.69 52 37.7 47 33.2 36 84.9 
- - 40 44.12 42 95.97 55 37.6 48 32.7 39 84.4 
- - 43 43.94 43 91.89 56 35.9 49 32.9 40 78.6 
- - 46 42.94 44 90.69 57 37.2 50 32 41 79.6 
- - - - 45 90.72 58 38.5 53 31 42 80.3 
- - - - 50 88.79 59 32.2 - - 43 74.6 
- - - - 51 86.59 62 32.9 - - - - 
- - - - 52 85.5 63 33.5 - - - - 
- - - - - - 64 28.9 - - - - 
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Table 3.5 Tomotherapy patients‘ data (subscript denoting patient number) 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
0 32.6 0 173.5 0 41.2 0 132.3 0 4.76 0 171.3 
3 30.5 3 178 3 42.2 1 129.3 1 3.79 1 173.8 
4 29.7 4 175.5 4 42.3 4 131.4 2 3.75 2 173.7 
5 30.2 5 175.9 5 42.4 5 139 3 3.69 3 179.6 
6 31.4 6 174.6 6 38.8 6 139.9 6 3.79 7 181 
7 31.1 7 171.6 7 38.4 7 133.9 7 4.11 8 179.4 
10 29 10 167.2 10 33.9 11 128 8 3.85 9 175.3 
11 28.2 11 168.3 11 33.4 12 126 9 4.38 10 176.5 
12 27.8 12 162.9 12 33.2 13 124.2 10 3.559 14 176.7 
13 26.1 13 159 13 32.9 14 125.9 13 4.67 15 186.9 
14 24.4 14 157.6 14 33.3 15 121.5 - - 16 198.7 
17 23.9 17 148.2 17 34.1 18 130.1 - - 17 200 
18 24.3 18 147.1 18 33.9 19 120 - - 23 196.6 
19 25.5 19 149.9 19 33 20 120.1 - - 24 194 
20 26.1 20 143.9 20 33.7 21 118.5 - - 27 198.5 
21 25 25 137 21 32.6 22 112.9 - - 28 193.8 
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24 22.4 26 136.3 24 30.9 27 114.6 - - 29 175.9 
25 21.1 27 136.6 26 30.5 28 122.9 - - 30 183.6 
26 20.4 28 134.2 27 32.4 29 116 - - 31 180.3 
38 21.1 31 129.6 28 32.6 33 106.4 - - 34 147 
39 20.1 32 127.4 31 30.1 34 104 - - 35 145.4 
40 20.2 33 128.3 32 30 35 101.6 - - 36 136.9 
41 19.7 34 123.5 33 30.6 36 101.7 - - 37 145.7 
42 16.2 35 119 34 31.4 39 105.1 - - 38 141.7 
45 14.8 38 126 35 30 40 90.9 - - 41 140.1 
46 14.3 39 128.4 39 27.3 41 104.3 - - - - 
47 13.4 40 124.1 40 26.7 42 96.3 - - - - 
48 14.1 41 124.3 41 25.3 43 98.7 - - - - 
- - 42 120.8 42 26 46 93.6 - - - - 
- - 45 108.4 45 25.1 47 90.3 - - - - 
- - - - 46 23.9 - - - - - - 
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Table 3.6 Tomotherapy patients‘ data (subscript denoting patient number) 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
    
      
      
      
 
0 3.2 0 37.55 0 35.73 0 10.99 0 115.3 0 65.04 
1 2.6 1 36.98 1 34.14 1 11.25 3 118.2 1 57.05 
4 2.7 2 43.1 3 39.82 2 10.477 4 118.2 2 57.95 
5 2.7 3 38.25 4 35.25 5 10.27 5 119.3 3 60.15 
6 3.3 4 37.32 7 37.74 8 10.85 6 120.1 6 58.24 
7 2.7 9 36.8 8 33.97 9 10.498 7 118.2 7 54.52 
8 3.3 10 38.17 9 30.61 12 9.31 11 119.4 8 57.69 
12 3 11 37.39 10 35.35 14 9.58 12 120.2 9 58.54 
13 3.3 15 32.74 11 34.33 15 8.59 13 120.9 10 55.76 
14 3.2 16 37.68 21 38.93 16 8.17 14 120 14 60.36 
15 3.3 17 36.55 22 27.61 19 9.69 17 116.9 15 58.93 
18 2.8 18 34.55 24 36.63 20 9.44 18 115.5 16 56.96 
19 3.2 21 33.69 25 38.59 21 8.3 19 108.9 30 54.92 
20 3.3 22 34.75 28 37.53 23 9 20 108.1 31 54.91 
21 3 23 37.77 29 35.08 26 9.355 21 100.1 34 59.18 
22 2.9 24 36.88 30 35.98 27 8.1 24 100.4 35 61.25 
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25 2.8 25 36.3 31 36.94 28 9.5 25 94.5 36 57.84 
26 2.7 28 33.64 32 36.91 29 8.34 26 92 37 58.37 
28 2.4 29 34 35 37.94 30 8.75 27 85.3 38 60.15 
29 2 30 39.59 36 33.12 33 9.44 28 80.4 41 59.66 
33 2.4 31 35.83 37 30.82 34 9.31 31 86.6 42 55.71 
34 1.6 32 34.44 38 31.85 35 9.19 32 85.2 43 55.66 
35 2 35 31.84 39 33.25 36 8.76 34 82.7 44 55.81 
36 2.2 36 32.19 42 33.01 40 9.94 38 84.7 45 53.4 
39 2.1 37 33.68 43 31.01 41 9.99 40 86.5 48 57.26 
40 1.3 38 31.39 44 32.92 42 8.55 41 85.3 - - 
41 0.9 42 31.97 45 29.85 43 9.5 42 83 - - 
42 2.3 43 32.73 46 29.38 47 7.64 45 82.8 - - 
43 1.9 44 31.75 49 28.96 48 7.661 46 83.8 - - 
- - - - 50 30.42 49 8.657 47 88.8 - - 
- - - - 51 27.46 50 8.42 48 89.7 - - 
- - - - - - 51 9.49 - - - - 
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